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NAFLD Non-alcoholic fatty liver disease 
TNF α Tumor necrosis factor α 
TNFR1 Tumor necrosis factor receptor 1 
PAI-1 Plasminogen activator inhibitor 1 
Akt Protein kinase B 
SREBP-1 Sterol regulatory element-binding protein 1 
ALT Alanine aminotransferase 
FAS Fatty acid synthase 
ATP Adenosine triphosphate 
AMPK Adenosine monophosphate activated protein kinase 
CCL2 Chemokine (C-C motif) ligand 2 
CCL19 Chemokine (C-C motif) ligand 19 
ICAM-1 Inter-cellular adhesion molecule 1 
PEPCK Phosphoenolpyruvate carboxykinase 
ApoB Apolipoprotein B 
CD1d Cluster of differentiation 1d 
HGF Hepatic growth factor 
IFN γ Interferon gamma γ 
IL15 Interleukin 15 
MTTP Microsomal triglyceride transfer protein 
NK1.1 Natural killer 1.1 
PI3K Phosphoinositide 3-kinase 
RBP4 Retinol binding protein-4 
VLDL Very low density lipoprotein 
BCL XL B-cell lymphoma-extra large 
GLUT 4 Glucose transporter type 4 
AML 12 Alpha mouse liver 12 
uPA Urokinase-type plasminogen activator 
iNKT cells invariant natural killer T cells 
  
 
 
 
CD3ζ Cluster of differentiation 3ζ 
LPS Lipopolysaccharide 
RNA Ribose nucleic acid 
PCR   Polymerase chain reaction 
RT-PCR reverse transcription polymerase chain reaction 
iNOS Inducible nitric oxide synthase 
FCS Foetal calf serum 
SDS Sodium dodecyl sulfate 
DTT 1,4 Dithiothreit 
TEMED Tetramethylethylenediamine, 
EDTA Ethylenedinitrilotetraacetic acid 
dNTP Deoxyribonucleotide triphosphate 
BSA Bovine serum albumin 
HCl Hydrochloric acid 
APS Ammonium persulfate 
PBS Phosphate buffer saline 
NO Nitric oxide 
µM Micro molar 
ng Nano gram 
mM Milli molar 
h Hours 
OD Optical density 
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1 Introduction 
 
1.1 Prevalence and mechanism of non-alcoholic fatty liver 
disease (NAFLD)  
Non-alcoholic fatty liver disease (NAFLD) is one of most common liver disease 
worldwide, affecting almost 30% of the general population in developed countries (data 
from US) and 10% of the general population in developing countries (1). NAFLD, as the 
name indicates occurs in the absence of significant alcohol consumption (<20 g ethanol/d) 
or other known causes of steatosis such as abuse of drugs or toxins. Histologically, the first 
stage of NAFLD is steatosis and this can continue to steatohepatitis finally leading to 
fibrosis and cirrhosis. Historically, steatosis was thought to be benign state of liver disease; 
however, recent studies (2) have indicated that fatty livers are more vulnerable to injury 
from various causes and can progress to steatohepatitis, increasing the probability of 
further liver-related morbidity and mortality (3). Worldwide, the prevalence and incidence 
of NAFLD is increasing as the worldwide prevalence of overweight and obesity increased 
and the developing countries shifting towards a western lifestyle. In general NAFLD 
affects substantial proportion of general population from several countries. The prevalence 
of NAFLD in the selected study populations in different countries is summarized in Table 
1. 
 
Table 1: Recent studies on prevalence of NAFLD in different countries in the selected study population 
Author Country Prevalence of NAFLD % 
Browing 2004 (4) USA 31% 
Bedogni 2005 (5) Italy 23% 
Luyckx 1998 (6) Belgium 74% 
Fan 2005 (7) China 15% 
Dixon 2001 (8) Australia 71% 
Park 2006 (9) South Korea 16% 
Kamikowski 2007 (10) Brazil 35% 
Das 2010 (11) India 10% 
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In the past 30 years, the prevalence of NAFLD has increased paralleling that of obesity, 
type 2 diabetes and metabolic syndrome. However, recent epidemiological studies suggest 
that certain dietary patterns (e.g. diet rich in fructose) may also be associated with an 
increased risk to develop NAFLD (for overview see (12)). 
 
Mechanism of NAFLD 
 
Several animal and human studies suggest that an increased intestinal permeability and 
endotoxemia may be involved in the pathogenesis of NAFLD (13-15). Indeed, Bode et al. 
were the first to report that endotoxemia is not only associated with alcoholic cirrohsis 
patients but also in non-alcoholic cirrohsis patients (16). Moreover, results of Wigg et al. 
suggest that the prevalence of intestinal bacterial growth, intestinal permeability and 
endotoxemia is increased in NASH patients (17). Recent studies in 35 biopsy proven 
NAFLD patients and health volunteers by Miele et al. revealed that NAFLD is associated 
with increased intestinal permeability due to an increased prevalence of small intestinal 
bacterial overgrowth (18). Furthermore, we recently showed that NAFLD patients have an 
altered intestinal permeability, higher endotoxin levels and that this was associated with an 
elevated expression of the endotoxin receptor toll like receptor-4 (TLR-4) (19, 20).  
 
In support of these human studies, we also recently reported that chronic fructose 
consumption in mice (30% fructose solution) is associated with an increased intestinal 
translocation of bacterial endotoxin into the portal vein (21). Furthermore, in various 
settings of liver diseases (e.g. alcoholic liver disease) it was shown that endotoxin binds to 
the lipopolysaccharide binding protein (LBP) which is produced by hepatocytes (22). The 
binding of endotoxin to LBP facilitates the transfer of endotoxin to the membrane bound 
cluster of differentiation (CD14) thereby activating Kupffer cells (22). The activation of 
Kupffer cells is then mediated through Toll like receptor (TLR 4). The activation of TLR 4 
turns on to an intracellular signalling cascade, which is mediated via MyD88 (23). MyD88 
associates with interleukin-1 receptor-associated kinase (IRAK) and tumour necrosis factor 
(TNF) - activated factor-6 (TRAF 6). This in turn results in the translocation of nuclear 
factor-κB (NF-κB) into the nucleus and the production of proinflammatory cytokines (e.g. 
TNF-α) (24, 25).  
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Furthermore, results of  Lida et al. showed that stimulation of Kupffer cells with endotoxin 
produce large amounts of the free radical nitric oxide (NO’) synthesized by the inducible 
form of nitric oxide synthase (iNOS) (26). The role of TNFα in the pathogenesis of 
NAFLD has been suggested before. For instance, animal studies have shown that 
antibodies against TNF improved NAFLD in obese mice. Furthermore, in diet induced 
(e.g. MCD diet, high fat diet) animal models of NAFLD an increased expression of TNFα 
has repeatedly been shown to be involved in the progression of the disease (27, 28). In line 
with these findings results of human studies have also shown an increased expression of 
TNFα in NAFLD patients (29). Additionally, we and others reported that patients with 
NAFLD have elevated hepatic and plasma levels of plasminogen activator inhibitor-1 
(PAI-1) in comparison to controls (19, 30). Moreover, it was also shown that plasma PAI-1 
levels and hepatic PAI-1 expression was increased in genetically obese mice (31). It has 
further been shown in animal models of acute alcohol-induced liver steatosis and in in vitro 
experiments that TNFα induced PAI-1 is involved in mediating the pivotal effect of TNFα 
on the liver (32). PAI-1 is an acute phase protein that inhibits fibrinolysis by inactivating 
urokinase-type and tissue-type plasminogen activator (33). PAI-1 has also lately been 
linked to the onset but also to the progression of liver diseases of various etiologies (e.g. 
alcohol, endotoxin) (for overview see (34)). For instance, in settings of alcohol-induced 
liver damage PAI-1 was shown to impair HGF/c-Met signaling cascade, which in turn 
impairs hepatic lipid export (32). However, how TNFα is involved in the onset of PAI-1 
and progression of NAFLD has not yet been determined. 
1.2 Fructose  
Fructose Intake 
Fructose is one of the main sugars consumed in diet besides glucose and sucrose. 
Sucrose is made of glucose and fructose to equal parts. Since 1970 sucrose (refined sugar) 
has more and more been replaced by High Fructose Corn Syrup (HFCS), a sugar derived 
from corn which contains 42-90% fructose in the United States (35, 36). In recent years 
sucrose is also more and more frequently replaced by fructose-glucose syrup containing at 
least 50% of fructose or plain fructose syrup in Europe.  
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Indeed in the US fructose consumption has increased five fold over the last century 
and in the last 30 years it’s doubled. Recent data from Vos et al. indicate that fructose 
consumption was ~ 15g/day before 1900. However, this had increased to ~24g/day before 
World War II and to ~55g/day by 1994. Today the daily intake is estimated to be ~73 
g/day (37). Reasons for this markedly increased intake may be the increased consumption 
of soft drinks and juice beverages containing sucrose or high fructose corn syrup (HFCS). 
For instance, food consumption studies (1965-1996) involving US adolescents revealed 
that there were large increases in the intake of soft drinks and non-citrus juices (38). In line 
with these findings results of Bray et al. indicate that the consumption of HFCS-55 
(sweetener used in soft drinks) in the US has increased by 1000% between 1970 and 1990 
(39). Recent results of an Italian survey on over 3300 subjects revealed that the mean daily 
consumption of soft drinks in Italy is as follows: 132g/day female adolescents, 203g/d in 
male adolescents, 114g/d in female adults, 147g/d in adult males (40) 
 
Fructose consumption and health 
Results of various studies in humans suggest that an excessive consumption of fructose 
is associated with clinical and biochemical symptoms of abdominal obesity, insulin 
resistance, dyslipidemia and the occurrence of metabolic as well as cardiovascular 
disorders (41). For instance, a cross-sectional study using data collected from the National 
Health and Nutrition Examination Survey (NHANES 2003 to 2006) involving 4528 adults 
without a history of hypertension revealed that a consumption of 74g/d fructose was 
associated with significantly higher blood pressure levels (42). Furthermore, the data 
analysis from the National Health and Nutrition Examination Survey over 6000 US adults 
revealed a significant correlation between consumption of caloric sweeteners (e.g. HFCS 
55) and blood lipid levels (43). The dietary and life style information collected by Finnish 
Mobile Clinic Health Examination Survey in Finland from 51522 non-diabetic men and 
women suggest that consumption of sweetened fruit juices and soft drinks is associated 
with an increased risk to develop diabetes (44). Furthermore, the results of Framingham 
Heart Study conducted in 6039 participants suggest that consumption of more than one can 
of soft drink per day is associated with occurrence of  metabolic syndrome (e.g. high blood 
pressure, waist circumference >35 cm females, >40 cm males, increased plasma 
triglycerides, increased fasting glucose, low HDL cholesterol) (45). 
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Additionally, weight gain was also observed in 14 diabetic men (11 with type 2 diabetes 
mellitus, 3 with type 1 diabetes mellitus) who consumed a diet supplemented with 50-60g 
fructose/d for 24 weeks (46). In a randomized controlled trail including 74 adult men 
consumption of 200g fructose/day for 2 weeks was associated with increased blood 
pressure levels and decreased high density lipoprotein levels (47). Consumption of fructose 
sweetened beverages for 10 weeks in 32 overweight or obese subjects resulted in the 
development of visceral obesity and increased lipoprotein levels in comparison to glucose 
consuming subjects. In addition, fasting plasma glucose levels, insulin levels and insulin 
resistance increased in subjects consuming fructose but not in subjects consuming glucose 
(48). Recently, results of Le et al. indicated that consumption of high fructose diet for one 
week in healthy young men increased fat deposition in the liver as well as in skeletal 
muscle (49). Taken together, the question if fructose intake is a general risk factor for the 
development of obesity has not been fully clarified; however, results of intervention 
studies, where excessive additional fructose was offered to participants indicate that 
elevated fructose intake is associated with the development of abdominal obesity. 
However, molecular mechanisms involved have not been fully understood.  
 
Cellular metabolism of fructose  
In the small intestine uptake of fructose is mediated through glucose transporter-5 
(GLUT5), located at both the apical lumen facing side of the intestine and the basolateral 
enterocytes facing membranes (Figure 1) (50).  
 
 
Introduction 
 
6 
Figure 1: Fructose and its hepatic metabolism. Glut 5 located at the intestinal membranes mediates 
fructose transport to portal blood. In the liver fructose is phospohorylated to fructose-1-phosphate, which is 
then further metabolized into glyceraldehyde, dihydroxyacetone phosphate. Thus, fructose enters the 
glyolytic pathway at the glyceraldehyde or dihydroxyacetone phosphate level respectively, thereby by- 
passing the major step of the glycolysis, which are controlled through insulin. Glut 5: glucose transporter 5, 
VLDL: very low density lipoprotein, ATP: adenosine tri-phosphate. 
 
The absorbed fructose is taken up by the liver with help of glucose transporter 2 (GLUT 2) 
(51, 52) so that only a modest escapes hepatic metabolism and enters systemic circulation. 
In the liver, fructose is phosphorylated by fructokinase to fructose-1-phosphate, which is 
then further metabolized into glyceraldehyde, dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate, respectively. Dihydroxyacetone phosphate and 
glyceraldehyde-3-phosphate may either be converted to glucose or triglycerides. Fructose 
thereby bypasses the major step in glycolysis, which is catalysed by the rate-limiting 
enzyme phosphofructokinase and is tightly regulated by insulin. Therefore, fructose can 
continuously enter the glycolytic/gluconeogenic pathway and produce glucose, glycogen, 
lactate and pyruvate without the control of insulin (Figure 1) (41, 53, 53). Pyruvate and 
lactate are then converted to acyl-glycerol, a molecule which is esterified leading to the 
formation of triglycerides and subsequently very-low-density lipoprotein (VLDL).  
 
Fructose and NAFLD  
 
Emerging evidences suggest that consumption of carbohydrate rich diet and herein 
particularly a fructose rich diet may be involved in the development of liver damage. 
Indeed, results of recent human studies carried out in the US in 427 adults revealed a link 
between increased consumption of fructose and hepatic inflammation and fibrosis (54). 
Zelber-Sagi et al. found a significant difference between the dietary patterns of NAFLD 
patients and controls in Israel. Specifically, NAFLD patients consumed larger amounts of 
sugar-sweetened soft drinks than the controls (55). 
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 These results were also confirmed in two small studies of our own group where we found 
that the total carbohydrate intake of patients with NAFLD did not differ from that of 
controls; however, fructose intake of patients with various stages of NAFLD (e.g. steatosis 
and steatohepatitis) was higher in comparison to controls (19, 20). Indeed, Thuy et al. 
reported that the total fructose intake was markedly higher by ~10g/day in NAFLD 
patients than in controls (19). In the US the assessment of dietary fructose intake in 
NAFLD patients  revealed that NAFLD patients consumed ~2.1-fold more HFCS 
containing sweets and beverages than controls (56). In support of these human studies, 
studies in rodents of our own group and others have also shown that increased 
consumption of fructose (e.g. 30-60 % of daily calories derived from fructose) may result 
in an increased lipid accumulation in the liver accompanied with insulin resistance, 
elevated plasma triglycerides levels and oxidative stress as well as hepatic tumor necrosis 
factor (TNFα) expression (21, 57-59). This effect was not found in mice concomitantly 
treated with antibiotics or deletion of TLR 4 or deletion of iNOS (21, 60, 61). Additionally, 
this protective effect of antibiotic treatment or deletion of iNOS is also associated with 
decreased phosphorylation of IĸB.  
 
Taken together, these studies suggest that chronic fructose consumption is associated with 
an increased lipid accumulation in the liver, inflammation and insulin resistance suggesting 
that besides de novo lipogenesis of fructose other mechanisms might also be involved in 
the pathogenesis of fructose-induced NAFLD. 
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1.3 Aims 
 
Worldwide the prevalence of overweight and obesity as well as insulin resistance 
associated diseases like NAFLD has increased throughout the last decades (41). Alterations 
of diet like an increased intake of refined sugar and herein particularly fructose are 
discussed as risk factors for the development of NAFLD (62). In recent years our own 
group has shown that chronic fructose intake in rodents is associated with an increased 
translocation of bacterial endotoxin from the gut and subsequently an activation of the 
TLR-4 signaling cascade in the liver (21, 60). However, molecular mechanisms involved 
in the damaging effects of fructose on the liver have not been clarified. Therefore, the aim 
of the present study is to investigate the role TNFα and PAI-1 in the onset of fructose-
induced NAFLD in a mouse model as well as in human NAFLD patients. The specific 
aims were: 
 
1) Are TNFR1-/- mice protected from fructose-induced NAFLD? If yes, what are the 
molecular mechanisms involved? 
 
2) Are PAI-1-/- mice protected from fructose-induced NAFLD? And if so, what are 
the molecular mechanisms involved? 
 
3) Are molecular mechanisms identified in mouse studies in regards to the 
development of NAFLD also relevant to human situation? 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Animals and treatments 
C57BL/6J mice Jackson, Main, USA 
TNFR1 -/- mice (Tnfrsf1atm1Mak/J) Jackson, Main, USA 
PAI-1 -/- mice (Serpine1tm1Mlg) Jackson, Main, USA 
Feed (Chow) ssniff® Spezialdiäten GmbH, Soest, 
Germany 
Cages 360cm2 Techniplast Deutschland GmbH, 
Hohenpeißenberg, Germany 
Ketamine BelaPharm GmbH, Fechta, Germany 
Xylazine Bayer AG, Leverkusen, Germany 
Fragmin® P Forte Pfizer Pharma GmbH, Karlsruhe, Germany 
Sodium chloride ≥99,8%    CarlRoth GmbH & Co, Karlsruhe, Germany 
Syringes 1ml B/Braun Melsungen, Melsungen, Germany 
Needles B/Braun Melsungen, Melsungen, Germany 
2.1.2 Cell culture and treatments 
AML-12 cells LGC Promochem, Wesel 
PAI-1 Sigma, Steinheim, Germany 
DMEM/F12 medium PAN Biotech GmbH, Aidenbach 
ITS PAA-Laboratories, Colbe, Germany 
Dexamethasone PAA-Laboratories, Colbe, Germany 
BSA Sigma, Steinheim, Germany 
FCS Biochrom AG, Berlin 
Penicillin/ Streptomycin  
(10.000 U Penicillin/ml) 
10mg Streptomycin/ml) 
PAN Biotech GmbH, Aidenbach 
PBS PAN Biotech GmbH, Aidenbach 
HGF Sigma, Steinheim, Germany 
Trypsin/EDTA solution PAA-Laboratories, Colbe, Germany 
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2.1.2 Human subjects and tissue collection 
RNA-later Ambion, England 
Aprotinin CarlRoth GmBH & Co, Karlsruhe, Germany 
EDTA tubes Sarstedt, Nümbrecht, Germany 
Li-heparin tubes Sarstedt, Nümbrecht, Germany 
 
2.1.3 Real time RT-PCR 
RNA isolation 
peqGOLD TriFast™ Pequlab Biotechnologie GmbH, Erlangen, 
Germany 
Chloroform >99% CarlRoth GmBH & Co, Karlsruhe, Germany 
Isoproponal >99.5%  CarlRoth GmBH & Co, Karlsruhe, Germany 
Ethanol absolute Merk, Darmstadt, Germany 
RNase free water Gibco/In vitrogen Corp., Karlsruhe, Germany 
 
cDNA synthesis  
5x MulV Buffer Fermantas GmbH, St. Leon-Rot, Germany 
DNase (1U/µl) Fermantas GmbH, St. Leon-Rot, Germany 
EDTA CarlRoth GmBH & Co, Karlsruhe, Germany 
Oligo dT Genaxxon Bioscience GmBH, Biberach, 
Germany 
dNTP Genaxxon Bioscience GmBH, Biberach, 
Germany 
MulV reverse transcriptase (20U/µl) Fermantas GmbH, St. Leon-Rot, Germany 
 
cDNA synthesis for PAI-1 
Baseline-Zero DNase Epicentre Biotechnologies, Madison, USA 
MMLV cDNA Synthesis Kit (No.: M5-
70702) 
Epicentre Biotechnologies, Madison, USA 
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PCR 
SYBR Green Applied Biosystems, Darmstadt, Germany 
All the primers used MWG-Biotech, Ebersberg, Germany 
12-well-Strips, 200µl Thin wall Bio-Rad Laboratories, Munich, Germany 
RT-PCR-i cycler Bio-Rad Laboratories, Munich, Germany 
 
2.1.4 Western Blotting 
 Cytosolic protein isolation 
HEPES CarlRoth GmBH & Co, Karlsruhe, Germany 
MgCl2 CarlRoth GmBH & Co, Karlsruhe, Germany 
KCl CarlRoth GmBH & Co, Karlsruhe, Germany 
Glycerol CarlRoth GmBH & Co, Karlsruhe, Germany 
EDTA CarlRoth GmBH & Co, Karlsruhe, Germany 
DTT CarlRoth GmBH & Co, Karlsruhe, Germany 
 
RIPA protein isolation 
MOPS CarlRoth GmBH & Co, Karlsruhe, Germany 
Nacl CarlRoth GmBH & Co, Karlsruhe, Germany 
Nonidet P-40 CarlRoth GmBH & Co, Karlsruhe, Germany 
SDS CarlRoth GmBH & Co, Karlsruhe, Germany 
Proteinase inhibitor cocktail Sigma Aldrich, Steinheim, Germany 
Tyrosine inhibitor cocktail Sigma Aldrich, Steinheim, Germany 
Ser/Thr phosphates inhibitor cocktail Sigma Aldrich, Steinheim, Germany 
 
Bradford assay 
Biorad dye Bio-Rad Laboratories, Munich, Germany 
BSA CarlRoth GmBH & Co, Karlsruhe, Germany 
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Gel preparation and blotting 
SDS CarlRoth GmBH & Co, Karlsruhe, Germany 
Tris –Base CarlRoth GmBH & Co, Karlsruhe, Germany 
HCL CarlRoth GmBH & Co, Karlsruhe, Germany 
Ammoniumpersulfate CarlRoth GmBH & Co, Karlsruhe, Germany 
Glycine CarlRoth GmBH & Co, Karlsruhe, Germany 
Methanol CarlRoth GmBH & Co, Karlsruhe, Germany 
Rainbow marker GE Healthcare Europe, Frieburg, Germany 
Acrylamide/Bis- solution (30 %) Bio-Rad Laboratories, Munich, Germany 
10% SDS Gibco/In vitrogen Corp., Karlsruhe, Germany 
TEMED Sigma Aldrich, Steinheim, Germany 
Ponceau S Solution Sigma Aldrich, Steinheim, Germany 
β-actin, Akt, AMPK, c-Met, phospho Akt, 
AMPK, c-Met, TNFα 
Cell Signaling Technology, USA 
Super signalling western dura kit Amersham Biosciences Europe GmBH, 
Frieburg, Germany 
 
2.1.5 Oil Red O staining 
Oil Red O Sigma-Aldrich, Steinheim, Germany 
Isopropanol ≥99,5%   CarlRoth GmbH , Karlsruhe, Germany  
Hematoxylin medite Medizintechnik, Burgdorf, Germany 
Immersion medium  medite Medizintechnik, Burgdorf, Germany 
OCT medite Medizintechnik, Burgdorf, Germany 
Glass slides Menzel GmbH & Co, Braunschweig, 
Germany 
Cryomold Sakura Finetek, Zoeterwoude, NL 
Microtome Leica CM3050J Leica Camera AG, Solms, Germany 
2.1.6 Naphthol AS-D chloroacetate esterase staining 
Naphthol AS-D Chloroacetate-   
Esterase-Kit (No.: 017K4339) 
Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Formalin 37% Merck, Darmstadt, Germany 
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Paraffin Histowax, 56-58°C Histolab Products, Göteborg, Schweden 
Filter paper for embedding cassette Vogel GmbH & Co. KG, Giessen, Germany 
Roti-Histol  CarlRoth GmbH & Co, Karlsruhe, Germany 
Ethanol absolute                                                           Merk, Darmstadt, Germany 
Aceton ≥99,8% CarlRoth GmbH & Co, Karlsruhe, Germany 
Immersion medium medite Medizintechnik, Burgdorf, Germany 
Paraffin station Leica EG1150H Leica Camera AG, Solms, Germany 
Cool plate Leica EG1150C Leica Camera AG, Solms, Germany 
Microtome RM2255 Leica Camera AG, Solms, Germany 
Embedding cassette Leica Camera AG, Solms, Germany 
Heater Thermo Electron Co., Langenselbold, 
Germany 
Glass slides Menzel GmbH & Co., Braunschweig, 
Germany 
Water bath MS Laborgeräte Schroeder OHG,  
Wiesloch 
 
 
2.1.7 Immunohistochemical staining 
Dako envision staining kit (Cat #K1390) Dako, Hamburg, Germany 
iNOS antibody Affinity Bioreagents, USA 
CD3ζ antibody Santa cruz Biotechnology, Heidelberg, 
Germany 
4-HNE antibody Cell Signaling Technology, USA 
PA1-1 antibody Santa cruz Biotechnology, Heidelberg, 
Germany 
Formalin 37% Merck, Darmstadt, Germany 
Paraffin Histowax, 56-58°C Histolab Products, Göteborg, Schweden 
Filter paper for embedding cassette Vogel GmbH & Co. KG, Giessen, Germany 
Roti-Histol  CarlRoth GmbH & Co, Karlsruhe, Germany 
Ethanol absolute  Merk, Darmstadt, Germany 
Aceton ≥99,8% CarlRoth GmbH & Co, Karlsruhe, Germany 
Immersion medium medite Medizintechnik, Burgdorf, Germany 
Paraffin station Leica EG1150H Leica Camera AG, Solms, Germany 
Cool plate Leica EG1150C Leica Camera AG, Solms, Germany 
Microtome RM2255 Leica Camera AG, Solms, Germany 
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Embedding cassette Leica Camera AG, Solms, Germany 
Heater Thermo Electron Co., Langenselbold 
Glass slides Menzel GmbH & Co., Braunschweig, 
Germany 
Water bath MS Laborgeräte Schroeder OHG,  
Wiesloch 
 
2.1.8 Hematoxylin & Eosin staining 
Hematoxylin medite Medizintechnik, Burgdorf, Germany 
Eosin medite Medizintechnik, Burgdorf, Germany 
Paraffin Histowax, 56-58°C Histolab Products, Göteborg, Schweden 
Filter paper for embedding cassette Vogel GmbH & Co. KG, Giessen, Germany 
Roti-Histol  CarlRoth GmbH & Co, Karlsruhe, Germany 
Ethanol absolute                                                           Merk, Darmstadt, Germany 
Immersion medium  medite Medizintechnik, Burgdorf, Germany 
Paraffin station Leica EG1150H Leica Camera AG, Solms, Germany 
Cool plate Leica EG1150C Leica Camera AG, Solms, Germany 
Microtome RM2255 Leica Camera AG, Solms, Germany 
Embedding cassette Leica Camera AG, Solms, Germany 
Heater Thermo Electron Co., Langenselbold 
Glass slides Menzel GmbH & Co., Braunschweig, 
Germany 
Water bath MS Laborgeräte Schroeder OHG,  
Wiesloch 
 
2.1.9 Triglyceride isolation 
Chloroform CarlRoth & Co, Karlsruhe, Germany 
Methanol CarlRoth & Co, Karlsruhe, Germany 
BSA CarlRoth & Co, Karlsruhe, Germany 
PBS  
NaCl CarlRoth & Co, Karlsruhe, Germany 
Na2HPO4 CarlRoth & Co, Karlsruhe, Germany 
KH2PO4 CarlRoth & Co, Karlsruhe, Germany 
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Randox TRIGS Triglyceride-Kit (Nr.: 
121047) 
Randox Laboratories LTD., Crumlin, UK 
Triglyceride-Kit for cell culture Biovision, California, USA 
Polytron homogenizer Kinematica AG, Switzerland 
Sonicator Bandelin, Berlin, Germany 
96-well-plate BD Bioscience, Heidelberg, Germany 
 
2.1.10 Endotoxin assay 
Charles river Endosafe kit Charles River, L'ARBRESLE Cedex, France 
Glass tubes Sarsted AG & Co, Nümbercht, Germany 
Endosafe microtiter plate Greiner BioOne GmbH, Frickenhausen, 
Germany 
Endosafe pipette tips Sarsted AG & Co, Nümbercht, Germany 
 
2.1.11 Microsomal triglyceride transfer protein (MTTP) assay 
MTTP assay kit Chylos Inc. USA 
Tris CarlRoth & Co, Karlsruhe, Germany 
EGTA CarlRoth & Co, Karlsruhe, Germany 
MgCl2 CarlRoth & Co, Karlsruhe, Germany 
Isopropanol CarlRoth & Co, Karlsruhe, Germany 
96-well black microtiter plate Greiner BioOne GmbH, Frickenhausen, 
Germany 
 
2.1.12 Adenosine 5’-triphosphate (ATP) assay 
EnzyLight TM  ATP assay kit (EATP-100) BioAssay systems, CA, USA 
96-well black white plate Greiner BioOne GmbH, Frickenhausen, 
Germany 
 
2.1.13 Alanine aminotransferase (ALT) assay  
Alanine Aminotransferase EC 2.6.1.2 kit Randox Laboratories LTD., Crumlin, UK 
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2.1.14 Miscellaneous  
Disposable plastic pippetes Greiner BioOne GmbH, Frickenhausen, 
Germany 
Micropippetes Eppendrof, Hamburg, Germany 
Micropippete tips Sarsted AG & Co, Nümbercht, Germany 
Reaction tubes Eppendrof, Hamburg, Germany 
Falcons (15 ml, 50 ml) Greiner BioOne GmbH, Frickenhausen, 
Germany 
96 –Well-round-bottom –plates Greiner BioOne GmbH, Frickenhausen, 
Germany 
 
2.1.15 Preparation of working solutions and buffers 
1.5 M Tris HCl (pH 8.8): 90.75 g tris base was dissolved in 500 ml nano pure water and the 
pH was adjusted to 8.8 with concentrated HCl. 
 
0.5M Tris HCl (pH 6.8): 30 g tris base was dissolved in 500 ml nano pure water and the pH 
was adjusted to 6.8 with concentrated HCl. 
 
10 % APS: 1 g ammoniumpersulfate was dissolved in 10 ml nano pure water and stored at 
4 0C. 
 
10X Electrophoresis buffer: 30 g tris base, 144 g glycine, 10 g SDS was dissolved in 
1000 ml nano pure water and stored at room temperature. 
 
Transfer buffer: 2.9 g glycine, 5,8 g tris buffer, 0.37 g SDS, 200 ml methanol was dissolved 
in 1000 ml nano pure water.  
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Dignum A: Dignum A was prepared as follows 
Reagents Volume 
1M HEPES (pH 7.6) 100 µl 
1 M MgCl2 15 µl 
2 M KCl 50 µl 
1 M DTT 5 µl 
protease inhibitor cocktail 10µl 
ser/thr inhibitor cocktail 100µl 
tyrosine inhibitor cocktail 100µl 
final volume was adjusted to 10 ml with nano pure water  
 
 
RIPA buffer: 0.418g MOPS (20mM MOPS pH7.0), 0.816g Nacl (150mM Nacl), 0.029g 
EDTA (1mM EDTA), 1ml Nonidet P-40 (1% v/v), 0.1g SDS (0.1 % w/v) were dissolved in 
100ml of distilled water. From this stock solution 10ml was taken and protease inhibitor 
cocktails (10µl protease inhibitor cocktail, 100µl ser/thr inhibitor cocktail, 100µl tyrosine 
inhibitor cocktail) were added before protein isolation. 
 
Oil Red O stock solution: Oil red O stock solution was prepared by dissolving 300mg of Oil 
Red O powder in 100ml of isopropanol and stirred this thoroughly that no clumps are evident. 
Then the solution was filtered three times using Whatmann filter paper. 
 
Oil Red O working solution: 24ml of Oil Red O stock solution was dissolved in 16ml of 
distilled water and stirred thoroughly and set aside for 10 min.   
 
Fixative for Naphthol AS-D chloroacetate esterase staining: Fixative solution was 
prepared according to the instructions of manufacturer by mixing 2.5ml of citrate solution in 
6.5ml of acetone and 0.8ml of 37% formalin.  
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Naphthol AS-D chloroacetate esterase staining solution: To 40 ml of warm distilled water 
1ml of sodium nitrite solution and 1ml Fast Red Violet LB Base were added and mixed 
thoroughly: In this mixture 5ml of TRIZMAL and 1ml of Naphthol AS-D Chloroacetate 
Solution were added and stirred thoroughly. All the reagents used were in part of the kit. 
 
Phosphate buffer saline tween solution (PBST): In 1liter water 8g Nacl, 1.44g Na2HPO4, 
0.2g KCl, 0.24g KH2PO4 and 0.4ml Tween were dissolved and the pH was adjusted to 7.4.  
 
DMEM/F12 working medium: 450 ml DMEM/F12 medium was supplemented with 10 % 
inactivated FCS (50 ml), 5ml of Penicillin/Streptomycin, 5ml of ITS, 500µl of dexamethasone 
and stored at 4 0C. 
 
DMEM/F12 stravation medium: 450 ml DMEM/F12 medium was supplemented with 
0.01% BSA (50 ml), 5 ml of Penicillin/Streptomycin, 5ml of ITS, and stored at 4 0C 
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2.2 Methods 
2.2.1 Animals and treatments 
Six week old C57BL/6J, TNFR1 -/- mice (Tnfrsf1atm1Mak/J) or PAI-1 -/- mice (Serpine1tm1Mlg) 
(n=5-6 per group) were used for the experiments. All procedures were approved by the local 
Institutional Animal Care and Use Committee (IACUC). During the experimental period the 
mice were kept under controlled lighting and air conditions in the specific-pathogen-free area 
(SPF-range) of the animal facility at the University of Hohenheim. Mice were randomly 
divided into 4 groups and either fed plain water or water containing 30% fructose for a period 
of 8 weeks (Table 2) ad libitum.  
Table 2: Animal groups and feeding 
Experimental group Drinking solution Feed 
Wild-type control Water Standard chow 
Knockout control 
(e.g, PAI-1, TNFR1) 
Water Standard chow 
Wild-type fructose 30% fructose solution Standard chow enriched with 
protein 
Knockout fructose 
(e.g, PAI-1, TNFR1) 
30% fructose solution Standard chow enriched with 
protein 
 
It has been previously shown by our own group that the mice chronically exposed to 30% 
fructose solution reduced their food intake in comparison to water fed mice (21). Therefore, in 
this study mice exposed to fructose were fed a protein and micronutrients enriched chow to 
prevent malnutrition. Body weight was assessed weekly over the 8 weeks feeding period.  
2.2.2 Tissue collection 
After the 8 week long feeding period animals were anesthetized with 80 mg ketamin/ kg and 6 
mg xylazin/ kg body weight by i.p. injection. Blood was collected just prior to sacrifice from 
the portal vein in heparinised syringes, which was then transferred to tubes containing 15µl 
heparin and immediately placed on ice. Blood was centrifuged for plasma at 700 rpm for 
14min at 10°C and then stored until further processing at -80°C. For histological evaluation 
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portions of liver were either fixed in 4% PBS-buffered formalin for at least 24hrs or frozen-
fixed in OCT mounting media. For molecular analysis portions of liver tissue were frozen 
immediately in liquid nitrogen. 
2.2.3 Human subjects and tissue collection 
The samples used in the present study were obtained in the due course of the master thesis of 
S.Thuy. Characteristics of patients as well as exclusion criteria have been described before in 
that master thesis and in Thuy et al.(19). In brief, patients included in the study underwent 
partial liver resection (e.g. because of liver metastasis) or liver biopsies for medical reasons 
(n=18). Characteristics of study participants are summarized in Table 3.  
Table 3: Characteristics of patients with NAFLD and controls1 
 Control NAFLD patients 
N 6 12 
Sex, % female 66 25 
Age, y 47 + 7 55 + 4 
BMI, kg/m2 22.5 + 1.2 27.8 + 0.7* 
Leisure physical activity, yes/no 6/0 6/6 
Plasma ALT, U/L (0–40 U/L) 2 40 + 10 59 + 12 
Plasma AST, U/L (0–38 U/L) 2 39 + 10 39 + 5 
Plasma g-GT, U/L (0–40 U/L) 2 57 + 19 173 + 50 
Liver resection, n 6 7 
Liver biopsy, 3 n 0 5 
Basic illness4   
Malignancy, n 5 6 
Other, n 1 1 
Liver pathology   
Without NAFLD, n 6  
Steatosis, n  2 
Steatohepatitis, n  3 
Steatohepatitis with fibrosis, n  7 
 
1 Values are means of + SEM. *Different from controls, P<0.05. 2 Normal range (27). 3Biopsy taken for staging 
of NAFLD. 4Basic illness of subjects underwent liver resection. (Table adapted from Thuy et al.(19)) 
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Exclusion criteria was as follows: 1) consuming lipid-lowering drugs or drugs affecting lipid 
metabolism; 2) altered lipid and glucose metabolism (e.g. diabetes); 3) alcohol abuse and 
alcohol intake >15 g/d ethanol; 4) drug-induced hepatotoxicity; 5) infection with hepatitis B 
or C virus; and 6) impaired nutritional status. Blood samples were drawn from fasted patients 
and controls before surgical intervention or liver biopsy in special Li-heparin tubes containing 
0.1mg of aprotinin/ml of blood. The collected blood was centrifuged at 3000rpm for 10min 
and the plasma was stored at -800C. Liver tissue obtained through biopsy or during 
hepatectomy were immediately placed in RNAlater and stored at -800C or fixed in 10% 
buffered formalin until later analysis 
2.2.4 Cell culturing and treatments 
All experiments were performed using AML-12 cells purchased from LGC Promochem 
GmbH, Germany. The cells were cultured in a 25 cm2 flask containing DMEM/F12 medium 
supplemented with 10 % FCS, ITS, dexamethasone and antibiotics. 
Sub-cultivation of cells 
After attaining 70 % confluence the cells were splitted and transferred into a new flask 
(75 cm2) as follows: 
a) Media and PBS were pre-warmed in 37 0C warm water bath.  
b) The media was discarded and cells were washed with 10 ml of PBS twice.  
c) Cells were incubated with 3ml of 1X trypsin/EDTA solution for couple of minutes at 
37 0 C. 
d) After the cells detached, fresh media was added into the flask and cells were span at 
1200xg for 5 min  
e) The cells were transferred into a new culture flask and the volume of the medium was 
adjusted to 12 ml. 
f) The culture flask was incubated at 37 0 C in an incubator with CO2. 
 
For incubation experiments cells were plated in 6 well plates as follows:  
a) The cells were splitted as mentioned above; however, after spinning the cells 10 ml of 
fresh media was added and the cells were separated carefully by pipetting up and 
down. 
b) 400 µl of the cell suspension and 2 ml of fresh medium was pipetted into each well 
and incubated at 37 0 C in an incubator with CO2. 
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Cell treatments 
At 70 % confluence cells were serum starved for 18 hrs in starvation medium 
supplemented with 0.01% BSA, ITS as well as antibiotics. Cells were then challenged with 
10 ng/mL PAI-1 for 24 h. In addition, some cells were concomitantly treated with 20 ng/mL 
hepatocyte growth factor (HGF). Cells were rinsed twice with phosphate buffer saline (PBS) 
and either used for triglyceride isolation or measurements of microsomal triglyceride transfer 
protein (MTTP) activity as detailed below (see section 2.2.12 & 2.2.14). 
 
2.2.5 Real time – polymerase chain reaction 
RNA isolation 
 
Total RNA was extracted from liver tissue samples using Trifast reagent according to the 
instructions of the manufacturer. In brief, the phenol-based reagent used for RNA isolation 
disrupts the tissue and the lysate is mixed with chloroform followed by centrifugation. 
Centrifugation separates the mixture into three phases, RNA is precipitated by isopropanol in 
aqueous phase.  
Liver tissue was homogenised in 1 ml of Trifast reagent and incubated for 5 minutes at room 
temperature. After shaking samples vigorously for 15 sec, 0.2 ml of chloroform was added 
and the lysates were kept at room temperature for 3-10 minutes. During centrifugation at 
12000 xg and 4 0C the mixture separates into the lower red (phenol-chloroform phase), the 
interphase and the colourless upper aqueous phase. The aqueous phase was transferred into a 
fresh tube and 0.5 ml of isopropanol was added to precipitate the RNA. Samples were placed 
on ice for 15 minutes, followed by a centrifugation for 10 minutes at 4 0C and 12000 xg. The 
supernatant was carefully removed and the RNA pellet was washed twice with 75 % ethanol 
by vortexing and subsequent centrifugation for 8 minutes at 7500 x g (4 0C). Excess ethanol 
was removed and the RNA pellet was air-dried. The pellet was resuspended in 10 µl of DNase 
and RNase free water and the samples were incubated at 55 0C for 10 minutes. RNA was then 
stored at –80 0C until further use. 
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Determination of RNA concentration and purity: To determine concentration, RNA was 
diluted (1:50) in a 96-well coaster UV plate with RNase and DNase free water. The 
absorbance was measured at a wavelength of 260/280 nm. The concentration was calculated 
as follows: 
Dilution = 2 μl of RNA sample + 98 μl distilled water (1:50 dilution). 
Concentration of RNA sample = 40* A260* Dilution factor 
RNA purity and integrity was determined by running 1% agarose gel. 28S and 18S rRNA 
bands were inspected to judge the quality. 
 
 c-DNA Synthesis 
To determine mRNA concentration, mRNA is transcribed into cDNA using of special enzyme 
called reverse transcriptase. In brief, the oligo(dT) primer anneals selectively on the poly(A) 
tail of mRNA, which acts as the anchor for reverse transcriptase. One µg of total RNA was 
diluted to a final volume of 20 µl using RNase and DNase free water. Five µl of 5X MuLV 
buffer and 1 µl of DNase was added to the RNA samples and the samples were incubated for 
15 minutes at 37 0C. The reaction was stopped by adding 2.5 µl of 25 mmol EDTA followed 
by an incubation at 70 0C for 10 minutes. To each sample 5 µl 5X MuLV buffer, 2.5 µl 
oligo(dt), 4 µl dNTP, 1 µl MuLV reverse transcriptase, 9 µl H2O were added and the mix was 
incubated for 1 h at 37 0C. After the incubation 50 µl of H2O was added to have a final 
volume of 100 µl of cDNA. cDNA synthesis for measuring PAI-1 mRNA expression was 
performed by using Epicentre cDNA synthesis kit as follows: 
 
1μg RNA/ μl in 8,11 μl 
Dnase-mix: 
10xBuffer Zero B. 0,96 μl 
DNase Zero B 0,84 μl 
Incubation: 20 min at 37°C 
Stopping the reaction: 
Stop Solution 0,95 μl 
Incubation: 10 min at 65°C 
cDNA-Synthesis: 
OligodT Primer 2 μl 
Incubation: 2 min at 65°C  and 1 min on ice 
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10xMMLV RT Buffer 2 μl 
DTT 2 μl 
dNTP 2 μl 
RNase Inhibitor 0,5 μl 
Reverse transcriptase 1 μl 
Incubation: 5 min at 85°C and 1 min on ice 
RNase-free Water 20 μl 
   
 Real time Polymerase Chain Reaction 
The concentration of PAI-1, Apo B, SREBP-1, FAS, CCL2, CCL19, ICAM-1, PEPCK Glut-
4, RBP-4, glucokinase, NK1.1, CD1d, CD3ε, IL-15, IFNγ, BCL XL, 18S mRNA human IRS-
1, human CD1d, human CD3ε, human MTP, human cMet, human IL-15, human IL-4, human 
BCL2l and human ß-actin mRNA in the liver tissue was determined by real time PCR using 
an I cycler (BioRad). The comparative threshold method was used to analyse the data 
obtained. The comparative Ct method is also known as the 2–[
δ][δ] Ct 
method, where 
[δ][δ]Ct = [δ]Ct,sample – [δ]Ct,reference 
With [δ]Ct, reference being the Ct value of the endogenous housekeeping gene.  
 
The PCR reaction mixture was prepared as follows:   
10 µl Sybr-Green 
3µl H2O 
1 µl forward primer 
1 µl reverse primer 
5 µl of sample  
The sequences of the primers used in the reaction mixture are summarized in Table 4. 
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Table 4: Primer sequences used for the detection of hepatic mRNA expression in mouse or human liver 
samples  
                  Forward (5’-3’)                        Reverse (5’-3’) 
Conc. 
nmol/L 
PAI-1 5’ TCC AAG GGG CAA CGG ATA GA 3’ 
 
5’ GAC GAA GAG CCA GGC ACA CA 3’ 300  
ß-actin 5’-GGC TCC CAG CAC CAT GAA-3’ 
 
5’-AGC CAC CGA TCC ACA CAG A-3’ 300 
Apo B 5’ TCA CCA TTT GCC CTC AAC CT 3’ 5’ CAG GTC AAC ATC GGC AAT CA 3’ 
 
300 
SREBP-1 5’ ACC GGC TAC TGC TGG ACT GC 3’ 
 
5’AGA GCA AGA GGG TGC CAT CG 3’ 300 
FAS 5’ GGG GGT GGG AGG ACA GAG AT 3’ 
 
5’ CAC ATG GGC TGA CAG CTT GG 3’ 300 
CCL2 5’ GCC AGA CGG GAG GAA GGC CA 3’ 
 
5’ TGG ATG CTC CAG CCG GCA AC 3’ 300 
CCL19 5’ GTC GGA GCC TCG GCC TCT CA 3’ 
 
5’ CCA CCC AGG GCT GGT CTG GA 3’ 300 
ICAM-1 5’ ACT GGA TCT CAG GCC GCA AG 3’ 
 
5’ GCC CTC CCA GCT CCA GGT AT 3’ 300 
PEPCK 5’ CCC TGG GAG ATG GGG AGT TC 3’ 
 
5’ CCC ACC ATA TCC GCT TCC AA 3’ 300 
18S 5’ GTA ACC CGT TGA ACC CCA TT 3’ 
 
5’ CCA TCC AAT CGG TAG TAG CG 3’ 300 
NK1.1 5’ GGC AGC TGT GCC TCC ATC  TT 3’ 
 
5’ CAC AGA TCT GGT GCG GAT GG3’ 300 
CD 1d 5’ TGT GTA CCA GTC CGG GAG CA 3’ 
 
5’ GTG CGG GAC CAG CTT CTG TT 3’ 300 
CD 3ε 5’ ATG GCC AAG AGC TGC CTC AG 3’ 
 
5’ TGA CCA TCA GCA AGC CCA GA3’ 300 
IL-15 5’ ATG TGA GGA GCT GGA GGA GA 3’ 
 
5’ ACG TTA GTT TGC CCA GCA GA3’ 400 
IFNγ 5’  CAA GCG GCT GAC TGA ACT CA 3’ 
 
5’ CAC TGC AGC TCT GAA TGT TTC TTA TT 3’ 300 
BCL XL 5’ ATG GCA GCA GTG AAG CA AG 3’ 
 
5’ GCA ATC CGA CTC ACC AAT ACC 3’ 300 
RBP-4 5’ TGC AGA CAT GGT GGG CAC TT 3’ 
 
5’ ACC AGC CTC CGT GTC TCT GG 3’ 300 
GLUT-4 5’ ACC  CCT CAT TCC CCC TGT GT 3’ 
 
5’ ACA  CAC CCA CCC CTG CTG TT 3’ 300 
Glucokinase 5’ACT TTC CAG GCC ACA AAC A 3’ 
 
5’ TCC CAG AAC TGT AAG CCA CTC 3’ 300 
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Human 
IRS 1 
5’  GTC TGG CCC GGT GGC TTT CC 3’ 
 
5’ GTG CTC TCC TGC CAG GCT GC 3’ 300 
Human 
CD1d 
5’ CCA GGT GTC CGC TGG CTG TG 3’ 
 
5’ TGG GGC CTC TTG GGT TGG CT 3’ 300 F 
 400 R 
Human 
BCL 2l 
5’ AAACTGGGTCGCATTGTGG 3’ 5’ TCTCGCCTGCTGCATTGTTC 3’ 300 
Human 
MTTP 
5’ CGG GGC GGG GTC TGG AGT TA 3’ 5’ TGG CAG CCA GTG AGG GAG TGA 3’ 300 
Human  
cMet 
5’ CCC AGC CCC TCT GCT TTC TT 3’ 5’ ATG GCT CCT CTG CAC CAA GG 3’ 300 
Human 
ß actin 
5’  GCA AGA GAG GCA TCC TCA CC 3’ 
 
5’ CGT AGA TGG GCA CAG TGT GG 3’ 300 
Human 
IL 4 
5’ GCC GGCAACTTTGTCCAC GG 3’ 5’ TCT GTT ACG GTC AAC TCG GTG CA 3’ 300 
Human 
IL 15 
5’ CTG CAG CCA GGA CTC GAT GGA GAA 
3’ 
5’ GCT CCA TGT GAC GTC AGC AGC A 3’ 300 
 
2.2.6 Western Blotting 
Cytosolic protein isolation  
To obtain the cytosolic protein fraction liver tissue was homogenised in 400 µl of dignum A 
solution by using a glass homogenizer. The suspension was transferred to a 1.5 ml reaction 
tube and was incubated on ice for 15 minutes. Thirty µl of a 10 % NP-40 solution was added 
to each tube and the tubes were vortexed vigorously for 10 sec. The samples were then 
centrifuged at 4 0C for 30 sec and the supernatant with cytosolic protein was transferred into a 
fresh tube.  
 
RIPA protein isolation 
To obtain total protein lysate liver tissue was homogenised in 1ml of RIPA buffer with a 
polytron until no visible tissue chunks are left. The samples were sonicated for 10 sec and 
vortexed at full speed. Samples were centrifuged at full speed (40C) for 5 min. The 
supernatant was stored in a fresh tube at-800C until further use. 
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Bradford assay 
Bradford assay was used to determine protein concentration. The assay is based on the 
binding of G-250 dye to proteins at arginine, tryptophan, tyrosine, histidine and phenylalanine 
residues. The dye binds to these residues in the anionic form, which has an absorbance 
maximum at 595 nm (blue). A standard reference curve for the protein was prepared as 
follows: 
 
Dignum A or RIPA solution was diluted in H2O (ratio1: 50), Biorad dye 5ml was diluted with 
20 ml of dH2O. Protein standard stock solution (BSA, 1 mg BSA/ml) was thawed and 
different standards were prepared as described in Table 5. 
 
Table 5: Preparation of the standard curve for the Bradford assay 
S: NO Concentration Dilution 
S1 1 mg BSA/ml 2 µl BSA stock+198 µl diluted dignum A/RIPA 
S2 0.5 mg BSA/ml 100 µl S1+100 µl diluted dignum A/RIPA 
S3 0.25 mg BSA/ml 100 µl S2 + 100 µl diluted dignum A/RIPA 
S4 0.125 mg BSA/ml 100 µl S3 + 100 µl diluted dignum A/RIPA 
S5 0.0625 mg BSA/ml 100 µl S4 +100 µl diluted dignum A/RIPA 
S6 0 100 µl diluted dignum A/RIPA 
 
Samples were diluted with water (1:50). In a 96-well plate 5 µl of sample or standard per well 
and 200 µl of diluted dye were mixed and incubated for 5 minutes at room temperature. 
Protein concentration of standard and samples were determined in triplicates. The plate was 
incubated for 5 minutes and measurements were carried out at 595 nm. A standard curve was 
generated and average absorbance value of each concentration of the protein standard was 
determined as a function of X with protein concentration as a function of Y  
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According to the concentration, the samples were diluted with 2 x sample buffer (without 
DTT) and dignum A or RIPA so that the final concentration in each sample was 4 or 6µg 
protein/µl sample. The samples were stored at –80 0C until further use. 
 
Gel preparation for Western blotting 
To determine the protein concentration of phospho Akt, phospho cMet, phospho AMPK, Akt, 
AMPK, cMet, TNFα and β-actin protein samples were separated in a sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred from the gel to a 
polyvinylidene (PVDF) membrane using the semi-dry method (63). The transferred protein 
was subsequently detected by immunological methods.  
 
SDS-PAGE 
Glass plates, spacers and combs (15 wells) of the electrophoresis unit were thoroughly 
cleaned with isoproponal. The gel mix was prepared as described in Table 6. 
 
Table 6: Preparation of separation gel 
Reagents 8% 10 %            12% 15% 
Nano pure water 4.5 ml 4.17 ml 3.5 ml 2.35 ml 
Acrylamide/Bis- solution (30 %) 2.7 ml 3.33 ml 4 ml 5 ml 
1.5 Tris HCl (pH 8.8) 2.6 ml 2.6 ml 2.6 ml 2.6 ml 
10 % SDS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
10 % APS 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
TEMED 0.006 ml 0.006 ml 0.006 ml 0.006 ml 
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The gel was poured with a disposable pipette and covered with isoproponal. When the 
separation gel was polymerized, isoproponal was washed off 3 times with nano pure water. 
The stacking gel was prepared as described in Table 7 and poured on top using a disposable 
pipette. 
Table 7: Preparation of stacking gel. 
 
 
 
 
 
 
 
 
The comb was placed carefully in the gel. After the gel was polymerized, it was wrapped in 
wet paper towels soaked in water, kept in a foil and stored in the refrigerator overnight.   
Protein samples diluted with sample buffer were thawed on ice and 10 µl of the protein 
samples were transferred into a fresh tube. Two µl of a 100 mM DTT solution was added. 
Samples were heated at 95 0C for 5 minutes and immediately placed on ice. A coloured 
protein marker was also heated simultaneously. Samples and marker were centrifuged shortly 
at 4 0C. One x electrophoresis buffer (50 ml 10 x buffer + 450 ml water) was poured in the 
electrophoresis apparatus and the gel was loaded with the protein samples or the marker 
proteins, respectively. Proteins were separated at 110 V for 1 h 20 minutes.  
 
Blotting 
 
Whatman paper and the PVDF membrane were cut to the size of the gel (5 x 8 cm2). The 
PVDF membrane was activated with methanol for 10 sec and the activated membrane was 
equilibrated in transfer buffer for 10 minutes on a shaking table. Simultaneously, whatman 
papers were also soaked in transfer buffer and placed on the shaking table for 10 minutes. The 
gel was transferred into transfer buffer and gently shaked for a couple of minutes and then a 
gel-paper-membrane sandwich was arranged on the semi-dry-blotter as follows: 
Reagents 4 % 
Nano pure water 1.575 ml 
Acrylamide/Bis-solution (30 %) 0.250 ml 
0.5Tris HCl (pH6.8) 0.625 ml 
10 % SDS 0.025 ml 
10 % APS 0.025 ml 
TEMED 0.003 ml 
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whatman membrane - gel - PVDF membrane - whatman membrane.  
The proteins were transferred to the membrane at 1 mA/cm2 of membrane for 55 minutes. The 
membrane was removed from the sandwich assembly and dried for 1 h. Then the membrane 
was activated again with methanol and washed with nano pure water. The PVDF membrane 
was stained with Ponceau S solution and washed with water thoroughly to check the protein 
transfer. The marker band was marked according to the respective colours and the membrane 
was blocked with 2.5% BSA in Tris-buffered saline-Tween (TBST) for 45 minutes. The 
membrane was incubated with primary antibody (dilutions of all primary antibodies 1:500 in 
2.5 % BSA) overnight at 4 0C on a rocking table.After the overnight incubation the membrane 
was washed 3-times with TBST for 5 minutes and treated with the secondary antibody for 45 
minutes (depending on the primary antibody (e.g. anti-mouse or anti-rabbit) on a rocking table 
at room temperature. After the incubation with the secondary antibody (dilutions of all 
secondary antibodies; 1:5000 in 2.5% BSA) the membrane was washed again with TBST 3 
times for 10 minutes. The membrane was incubated with Super Signal Western Dura 
solutions (1:1 dilution,) for 5 minutes protected from light. A picture was taken under the gel 
documentation system (Alpha Innotech, USA) after incubation 
Densitometric analysis of blots 
Protein bands were densitometrically analyzed using the Flurochem Software. In this method 
the band of interest and the background were selected and analyzed for the specific protein 
concentration as follows: 
Protein concentration (e.g. TNFα) = Average of TNFα band- Auto-background/ Average of β 
actin band- Auto-background. 
Protein concentration of phosphorylated protein = Average of phosphorylated protein band – 
Auto-background/ Average of total protein band – Auto-background. 
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2.2.7 Oil red O staining 
Oil red O is a lipid soluble dye which is soluble in the tissue lipid than in the solvent it’s 
dissolved. Oil red O staining was done to reveal the lipid accumulation in liver. The lipid 
droplets appear red in colour after the staining. Frozen OCT mounted liver sections were cut 
at 10µm thickness with help of cryostat, dried for 2 min and immediately frozen at -200 C. 
The stock dye solution was prepared as described in section 2.1; stirred for an hour and 
filtered twice. Forty eight ml of filtered stock solution was diluted with 32 ml ddH2O and 
added directly to just thawed liver sections in the cuvette. After 15 min in the cuvette the 
sections were washed twice with ddH2O and checked for colour intensity under the 
microscope. Then the specimens were rinsed 5 min under running cold tap water and counter 
stained with hematoxylin for 45 sec. Excess staining was washed off under running tap water 
for 2-3 minutes. Nuclei in stained sections appear blue. Subsequently, the sections were 
briefly dipped in ddH2O and covered with one to two drops aqueous mount. Representative 
400x microscopic pictures were made by using Zeiss microscope in combination with 
AxioVision software release 4.5. 
 
2.2.8 Paraffin embedding of liver sections 
A formalin fixed paraffin embedded tissue is a piece of tissue which is immobilized and 
preserved for the purpose of staining. Fixation makes tissue permeable to staining reagents 
and cross-links its macromolecules so that they are stabilized and locked in position. Table 8 
summarizes fixing and paraffin embedding of liver tissue. 
 
Table 8: Paraffin embedding of tissue  
 
Treatment Incubation time 
4% Formalin ≥ 24 h 
Cold running tap water 
75% EtOH 1 h 
85% EtOH 1 h 
95% EtOH Over night 
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100% EtOH 1 h 
100% EtOH 1 h 
100% EtOH 1 h 
100% EtOH : Roti-Histol (1:1) 30 min 
Roti-Histol 1 h 
Roti-Histol 1 h 
Paraffin 30 min 
Paraffin 30 min 
Paraffin 30 min 
Embedding of tissue sections in paraffin 
Storage at -20 ° C 10 min 
 
2.2.9 Naphthol AS-D chloroacetate esterase staining to detect neutrophils 
For staining of neutrophils in the liver a commercially available kit from Sigma-Aldrich was 
used following the instructions of the manufacturer. The kit has Naphthol AS-D Chloroacetate 
which is enzymatically hydrolyzed by "specific esterase," liberating a free naphthol 
compound. This then couples with a diazonium salt, forming highly colored deposits at sites 
of enzyme activity. This enzyme is usually considered specific for cells of granulocytic 
lineage (e.g. neutrophils). The staining was performed in paraffin embedded liver sections as 
summarized in Table 9 
 
Table 9: Staining of tissue sections with naphthol AS-D chloroacetate esterase  
 
Cutting the tissue at 5µm thickness 
Drying the sections at 37°C 72 h 
Roti-Histol 10 min 
100% EtOH 5 min 
96% EtOH 5 min 
70% EtOH 5 min 
ddH2O 5 min 
ddH2O 5 min 
1-4 drops of fixative 30 sec 
ddH2O 60 sec 
Incubation of the sections at 37 ° C in the staining 
solution 
15 min 
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Staining was checked under microscope 
Counter stain with hematoxylin 15 sec 
Mount the sections with aqueous mount 
 
Using a Zeiss Axiovert 200M microscope and the AxioVision software release 4.5, neutrophil 
numbers in liver specimens were counted in 5 randomly selected fields (200x). 
2.2.10 Immunohistochemical staining of iNOS, 4-hydroxynoneal 
adducts (4 -HNE), CD3ζ, human 4 HNE, human PAI-1, human 4-HNE and 
human CD3ζ 
Immunohistochemical staining of iNOS, CD3 ζ, 4-HNE and PAI-1 was performed in the 
respective paraffin embedded liver tissue. The tissue was embedded, cut and deparaffinised as 
described previously in Table 8 and 9. The deparaffinised tissue sections were washed twice 
with PBS-tween. The tissue sections were blocked with peroxidase for 5 minutes and then 
washed once again with PBS-tween for 5 minutes. The tissue sections were stained either for 
4-hydroxynonenal-protein adducts or iNOS or CD3ζ or PAI-1 using respective polyclonal 
antibodies for 30 minutes at room temperature (Dilutions of primary antibodies; 1:500 in 
2.5% BSA). To detect specific binding of primary antibody, tissue sections were incubated 
with a peroxidase linked secondary antibody for 15 minutes and diaminobenzidine for 8 
minutes. The sections were washed under slow running tap water for 6 minutes and then 
stained with hematoxylin staining for 30 sec and sections were once again washed under 
running tap water. The sections were dehydrated and cover slips were mounted. Using a Zeiss 
Axiovert 200M microscope and the AxioVision software release 4.5, the extent of staining in 
liver sections was defined as percent of the field area within the default colour range as 
determined by the software. To determine means, data from 8 fields (200 x for 4-HNE, 630x 
with oil immersion for iNOS, CD3ζ and PAI-1) of each tissue section were used. 
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2.2.11 Hematoxylin and Eosin staining 
Hematoxylin and Eosin staining is the standard staining method used in histology and gives 
an overview of the structure of the tissue. It was used to evaluate liver pathology. The staining 
protocol is summarized in Table 10. 
Table 10: Staining of tissue sections with H & E 
Cut and deparaffinised the sections in the usual way 
(see Table 10, 11) 
 
Hemotoxylin solution 2-5 min 
Staining was checked under microscope  
Running tap water 10 min 
ddH2O  
40% EtOH 2 min 
Eosin aqueous solution 60-75 sec 
Staining was checked under microscope  
70% EtOH 30 sec 
96% EtOH 30 sec 
100% EtOH 30 sec 
Roti-Histol 10 min 
Mount the sections with aqueous mount 
 2.2.12 Triglycerides (TG) isolation 
Hepatic triglycerides were isolated using a method modified from that of Folch et al.(64) and 
the concentration of triglycerides was measured by using a commercially available kit 
following the instructions of the manufacturer. In brief, ~50mg of liver tissue was 
homogenized with ‘polytron’ in 1 ml of ice-cold 2x PBS. The homogenate was sonicated for 
20 sec at full speed. Five hundred µl of the homogenate was aliquoted and 750µl of a pre-
made chloroform/methanol mixture (2:1) was added to it. Then each sample was vortexed for 
10 sec in a span of 10 min. Samples were then incubated at room temperature for 2 hrs 
followed by a full speed centrifugation at 40C for 5 min. The bottom phase (400µl) was 
transferred into a new tube and dried in a centrifugation concentrator for 12 min.  
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The samples were resuspended in 5% BSA, sonicated for 10 sec at full speed and frozen at -
800C over night. To further breakup left over particles the samples were once again sonicated 
for 10 sec at full speed and warmed up to 370C. The enzyme reagent and standard were 
thawed at room temperature, two µl of standard or sample and 200µl of enzyme reagent was 
pipetted into 96 well round bottom plate. The plate was incubated at 370C for 5min.The 
spectrophotometer was also pre-warmed at 370C and then the plate was measured at 500nm. 
Hepatic triglycerides concentration was normalized with hepatic protein content. Accordingly, 
Bradford assay was performed as described in section 2.2.5.3 with the remaining liver tissue 
homogenate. The final hepatic triglyceride content was calculated as follows: 
              
         Absorbance (Sample) 
  Triglyceride [mg/dl]  =  Concentration (Standard) *  
 Absorbance (Standard) 
 
Final triglyceride (µg/mg) of protein =   TG concentration (Sample)/ Protein concentration (Sample) 
 
Triglycerides isolation from cells 
 
Triglyceride levels in cell cultures were determined using a kit from Biovision following the 
instructions of the manufacturer. In brief, cells were homogenized in 5% NP-40 solution and 
the samples were heated at 1000C in a water bath for 5 min until NP-40 became cloudy, then 
the samples were cooled down to room temperature. The heating step was repeated once again 
to solublize all triglyceride. The samples were centrifuged at top speed for 2 min to remove 
any insoluable material. The samples were then diluted with triglyceride assay buffer in 1:1 
ratio to final volume of 50µl/well. Triglyceride standard solution was prepared by adding 
40µl 1mM TG in 160µl assay buffer. A standard reference curve was pipetted as follows: 
 
Table11: Pipetting of standards for triglyceride assay 
S: NO Concentration Dilution 
S1 0mM 50µl of TG assay buffer 
S2 2mM 10µl 0 2mM TG + 40µl TG assay buffer 
S3 4mM 20µl 0 2mM TG + 30µl TG assay buffer 
S4 6mM 30µl 0 2mM TG + 20µl TG assay buffer 
S5 8mM 40µl 0 2mM TG + 10µl TG assay buffer 
S6 10mM 50µl 0 2mM TG   
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Two µl of lipase was added to each sample and standard wells. The plate was incubated at 
room temperature for 20 min to convert triglyceride to fatty acid and glycerol. Meanwhile, a 
reaction mix of 50µl/well was prepared by adding 46µl Triglyceride assay buffer, 2µl 
Triglyceride probe and 2µl Triglyceride enzyme mix. Reaction mix was added to each well 
and incubated at room temperature for 60 min in the dark. The reaction was measured at 
570nm in a microtiter plate. TG concentration was calculated as follows: 
 
Concentration of TG = Ts/Sv µmol/ml or mM 
Ts is triglyceride amount from the standard curve (nmol) 
Sv sample volume added in the sample wells (µl) 
2.2.13 Endotoxin assay 
Plasma endotoxin levels were determined using a commercially available endpoint Limulus 
Amebocyte Lysate assay kit which is dependent on a direct relationship between endotoxin 
concentration and colour development. In brief, plasma samples were diluted in 1:5 ratio to 
get an end volume of 70µl and heated at 70oC for 20 min. Meanwhile, different standards 
were prepared as follows: 
 
Table12: Preparation of standards for endotoxin assay 
S: NO Concentration Dilution 
S1 0 EU/ml 250µl Endosafe water 
S2 0.00195 EU/ml 250µl S3 + 250µl Endosafe water 
S3 0.00390 EU/ml 250µl S4 + 250µl Endosafe water 
S4 0.00781 EU/ml 250µl S5 + 250µl Endosafe water 
S5 0.01560 EU/ml 250µl S6 + 250µl Endosafe water 
S6 0.0312 EU/ml 250µl S7 + 250µl Endosafe water 
S7 0.0625 EU/ml 250µl S8 + 250µl Endosafe water 
S8 0.125 EU/ml 1.25µl (50EU/ml) + 498.75 Endosafe water 
 
Materials and Methods                                                                                                       
 
37 
 
Twenty five µl of standards or samples were pipetted in duplicates into a special endoasfe 
microtiter plate and incubated at 370C for 5 min. Then 25µl of Limulus-Amoebocyte-Lysate 
(LAL) was added and incubated at 370C for 5 min. After the incubation, 50µl of chromogen 
substrate/Buffer (1:1) mixture was added and once again incubated at 370C for 5 min. The 
colour reaction was stopped by adding 50µl of 20% acetic acid followed by reading the plate 
at 405nm. A standard curve was generated and average absorbance value of each 
concentration of the endotoxin standard was determined as a function of X with endotoxin 
concentration as a function of Y. The recovery rate of the assay was around ~70%. 
 
2.2.14 Microsomal triglyceride transfer protein (MTTP) activity 
Hepatic MTTP activity was determined using a commercially available MTTP assay kit 
following the instructions of the manufacturer. In brief, purified MTTP or cellular 
homogenates were incubated with donor vesicles containing fluorescent lipids and acceptor 
vesicles containing phosphatidylcholine and triacylglycerols. Increases in fluorescence were 
measured and credited to MTP-mediated lipid transfer. Liver tissue was homogenised in 1ml 
of ice-cold buffer containing 1mM Tris pH7.6, 1mM EGTA and 1mM MgCl2 and 50µl of 
protease inhibitors cocktail. Homogenisation was followed by a centrifugation of the samples 
at 7400xg for 30 min at 40C and the supernatant was transferred into fresh 1.5ml 
microcentrifuge tubes for protein measurement. 100µg was taken for determining the MTTP 
activity. Measurements were performed in triplicate in a black microtiter plate by pipetting 
the components provided in the kit and samples as shown in Table 13. 
 
Table 13: Pipetting of different components and samples for MTTP assay 
 Vesicles Water Sample Buffer Isopropanol MTP 
A. Blank 5µl 90µl  5µl   
B. Total 5µl    95µl  
C. Positive control 5µl 85µl  5µl  5µl 
D. Test 5µl 90µl 5µl    
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After pipetting, the plate was incubated for 30 min at room temperature and the fluorescence 
units were measured using excitation and emission wavelengths of 460-470 and 530-550nm, 
respectively. Following calculations were used to calculate the MTTP activity in samples. 
1) % Transfer in controls (C): (Control FU - Blank FU)/(Total FU - Blank FU)*100 
2) % Transfer in controls (D): (Test FU - Blank FU)/(Total FU- Blank FU)*100 
 
MTTP assay in cells 
Cells were washed twice with 1ml of ice cold PBS and rinsed with ice cold MTTP assay 
buffer. Then the cells were incubated with MTTP assay buffer at 370C for couple of minutes 
and the buffer was aspirated. Hundred µl of ice cold MTTP assay buffer containing protease 
inhibitors was added. The cells were scrapped and homogenized by passing through a 21 
gauge syringe needle. Homogenized cell suspension was centrifuged at top speed for 1h at 
40C.The supernatant was used for lipid transfer assay as described above. 
 
2.2.15  Adenosine 5’-triphosphate (ATP) assay 
ATP levels in liver tissue were determined by using a commercially available ATP assay kit. 
Tissue was lysated with assay buffer to release ATP. The released ATP reacts with D-
luciferin in presence of luciferase to produce light. The light intensity is a direct measure of 
intracellular ATP concentration. Liver tissue was homogenized in ice cold PBS and 
centrifuged at 12000 g for 5 min. The supernatant was diluted with PBS (1:5) to an end 
volume of 100µl and pipetted into a white opaque 96-well plate in triplicates. Simultaneously, 
1000µl of 30µM ATP premix was prepared by mixing 10µl of 3mM ATP standard in 990µl 
distilled water and diluted to generate a standard curve as shown in Table 14. Hundred µl of 
the standards was also pipetted in triplicates into the plate followed by 90µl of reconstituted 
reagent (reconstituted reagent: 95µl assay buffer + 1µl substrate + 1µl ATP enzyme). The 
plate was incubated at room temperature for 10 min and luminescence was measured at 
125 nm. 
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Table 14: Preparation of standard curve for ATP assay  
No Premix + water Vol (µl) ATP (µM) 
1  150µl+0µl 150 30 
2  120µl+30µl 150 24 
3    90µl+60µl 150 18 
4    60µl+90µl 150 12 
5   45µl+105µl 150 9 
6   30µl+120µl 150 6 
7   15µl+135µl 150 3 
8    0µl+150µl 150 0 
 
2.2.16 Alanine aminotransferase (ALT) assay 
Plasma ALT levels of mice were determined by using a commercially available Randox ALT 
assay kit following the instructions of the manufacturer. In brief, ALT enzymatic assay kit 
uses a coupled enzymatic reaction scheme in which alanine and α-ketoglutarate are first 
converted to glutamate and pyruvate after which the pyruvate is converted by lactate 
dehydrogenase to generate lactate and NAD+. The conversion of the NADH chromophore to 
NAD+ was measured at 340 nm, which is proportional to the level of ALT enzyme in the 
sample. Plasma was diluted 1:10 with water. 10µl of the diluted plasma and 100µl of 
reconstituted buffer containing substrate and enzyme were pipetted into the microtiter plate. 
The initial absorbance was measured at 1, 2 and 3min and the values of the first 2min were 
used for the calculation. 
ALT activity of sample (U/L) = 1746*δ A 340nm/min. 
2.2.17 Retinol binding protein 4(RBP-4) ELISA 
RBP-4 levels were determined using a commercially available ELISA kit following the 
instructions of the manufacturer. In brief, RBP/RBP4 in the samples is bound to polyclonal 
rabbit anti RBP/RBP4 antibodies, immobilized on the microtitre plate. A peroxidase-
conjugated anti RBP/RBP4 antibody is used for detection and quantification, and 
tetramethylbenzidine (TMB) as a peroxidase substrate.  
Materials and Methods                                                                                                       
 
40 
 
The precoated microtiter plate was washed 5 times with 250µl wash buffer. Hundred µl of 
standard, controls and samples were pipetted into the wells in duplicates. The plate was 
incubated for 1hr at room temperature on a horizontal mixer. The content of the plate was 
decanted and the wells were washed 5 times with 250µl of wash buffer followed by addition 
of 100µl of conjugate into each well. The plate was incubated for 1hr at room temperature and 
decanted, washed 5 times with 250µl of wash buffer. Hundred µl of substrate solution was 
added to each well and incubated for 20 minutes at room temperature by slightly shaking until 
colour differences are sufficient. Fifty µl of stop solution was added into each well and mixed 
shortly. The absorption was determined at 450nm against 620nm as a reference. A standard 
curve was generated and average absorbance value of each concentration of the RBP-4 
standard was determined as a function of X with RBP-4 concentration as a function of Y. 
 
2.2.18 Statistical analysis 
All results are expressed as means + SEM (Mice samples n=5-6) (Human subjects n=18).  
Results were statistically analysed using the analysis of variance test (ANOVA) or student t-
test included in the Graph pad prism software or SPSS. Normal distribution of the data was 
tested out with the Kolmogorov-Smirnov test and homogeneity of variances was tested with 
the Bartlett's test. Logarithmic transformation of raw data was performed in cases of unequal 
variances. Statistically significant differences were determined using Tukey’s post hoc test. P 
value < 0.05 was considered to be significant 
.
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3 Results 
3.1 Studies in TNFR 1-/- mice fed fructose 
3.1.1 Effect of fructose feeding on weight gain and liver to body weight 
ratio in TNFR 1-/- mice 
The body weight of mice was measured weekly. In table 17 absolute weight gain of mice 
throughout the 8 weeks of feeding is summarized. Absolute weight gain of wild-type controls 
was significantly lower than that of TNFR 1-/- mice fed water (~1.4g, p<0.05). When 
compared with their respective controls, absolute body weight gain of both fructose fed 
groups were significantly higher (wild-type: +~2g, TNFR 1-/-: +~3g both p<0.05, in 
comparison to respective controls). In both fructose fed groups not only absolute liver weight 
but also liver to body weight ratio was significantly higher than their respective controls 
(wild-type liver weight: +~0.3-fold, liver to body weight ratio: +~1-fold; TNFR 1-/-  liver 
weight: +~0.16-fold, liver to body weight ratio: +~1-fold, all p<0.05) (Table 15) 
 
Table 15 Effect of fructose feeding on body weight, liver weight and liver to body weight ratio in TNFR 1-
/- mice 
  
  Control  
+  Water 
 
TNFR1 -/-   
+ Water 
 
Control 
+ Fructose 
 
TNFR1 -/-  
+ Fructose 
Weight gain (g) 
 
3.1 + 0.1    4.5  +   0.3 5.1   +  0.7 a 7.6   + 0.5  a,b,c 
Liver to body weight ratio (%) 
 
4.8 + 0.1 5.12   +   0.1 5.9   +  0.1 a,b 6.2   + 0.1 a,b 
Absolute liver weight (g) 0.99 + 0.01 
 
1.16   + 0.03 a    
 
1.33 +  0.14 a,b 
 
1.63 + 0.07 a,b,c 
 
1 Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water. bp < 0.05 
compared with TNFR1 -/- mice fed with plain water. cp< 0.05 compared with wild-type fructose fed mice.  
Results                                                                                                       
 
42 
 
3.1.2 Effect fructose feeding on liver steatosis, inflammation and ATP 
levels in TNFR1-/- mice 
Liver steatosis 
Hepatic lipid accumulation was assessed by oil red O staining and quantitative analysis of 
hepatic triglyceride concentration. Liver pathology was assessed by hematoxylin and eosin 
(H&E) staining. Figure 2 depicts representative photomicrographs of hepatic hematoxylin and 
eosin (H & E), oil red O staining and quantitative analysis of hepatic triglyceride 
concentration in TNFR1 -/- and wild-type mice either fed water or water sweetened with 30% 
fructose for 8 weeks. H & E staining revealed no significant pathological changes between 
wild-type and TNFR1 -/- mice fed water (Figure 2A upper panel). In line with these findings 
lipid staining as well as hepatic triglyceride concentration was minimal in wild-type and 
TNFR1 -/- mice fed water (Figure 2A lower panel & B). In contrast, in wild-type mice 
chronic fructose feeding caused an ~5-fold increase in hepatic triglyceride levels in 
comparison to wild-type water fed mice (Figure 2B) (p < 0.05) whereas in TNFR1-/- mice it 
caused only an ~2-fold increase in hepatic triglyceride levels in comparison to water fed 
TNFR1-/- mice (Figure 2B) (p < 0.05). In the present study, plasma ALT levels were found to 
be significantly increased by ~6-fold in wild-type mice fed fructose in comparison to water 
fed wild-type mice. In contrast, plasma ALT levels of TNFR1 -/- mice fed fructose did not 
differ from that of the respective control mice fed water (Table 16). 
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Figure 2 Effect of fructose feeding on hepatic pathology, lipid accumulation and triglyceride levels. (A) 
Representative photomicrographs of hematoxylin and eosin (upper panel) and oil red O staining (lower panel) of 
liver sections (400x). (B) Quantitation of hepatic triglyceride content. Data are expressed as means ± SEM (n = 
4-6). W – water; F – 30% fructose solution. ap < 0.05 compared with wild-type mice fed with plain water.  bp < 
0.05 compared with TNFR1 -/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose fed mice.  
 
Liver inflammation and ATP levels 
In settings of steatosis and steatohepatitis TNFα may potentially induce chemokine secretion 
(like CCL2 and CCL19) and inflammation (for review see (65)) thus, number of neutrophils 
as well as expression of ICAM-1, CCL2 and 19 were determined (Table 16). Chronic fructose 
feeding in wild-type mice was associated with an increased number of neutrophils and 
expression of ICAM-1 in comparison to water controls (neutrophils: +~5.5-fold, ICAM-1: 
+~1.8-fold in comparison to wild-type water contols) (Table 16). Similarly, CCL2 and CCL19 
mRNA expression in livers of fructose fed wild-type mice was also increased; however, as 
expression varied considerable between animals, differences did not reach a level of 
significance (CCL2; p=0.38, CCL19; p=0.11 in comparison to wild-type water controls) 
(CCL2; p<0.05, CCL19; p=0.07 in comparison to TNFR 1-/- water controls) (see Table 16). 
In contrast, these effects of fructose feeding were not found in TNFR1-/- mice.  
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In addition, ATP concentrations were also determined in the present study, as it has been 
shown in humans and rodents that acute intravenous exposure to fructose can lead to a 
depletion of ATP (66) in the livers and this may be associated with alteration of both 
apoptotic and necrotic TNFR1-mediated liver damage. However, in the present study hepatic 
ATP concentration did not differ between the groups (see Table 16).  
 
Table 16 Effect of fructose feeding on ALT levels, inflammatory infiltration and expression patterns of 
chemokines as well as hepatic ATP concentrations1 
   Control  
+  Water 
TNFR1 -/-   
+ Water 
   Control 
+ Fructose 
TNFR1 -/-  
+ Fructose 
ALT (U/L) 2.7 + 0.8 3.4   +   0.9 16.1 +  4.1 a,b 5.4   +  0.9 c 
Neutrophil count 
 
0.2   +  0.03 0.2    +   0.08 1.1  +  0.09 a,b,d  0.33   +  0.05  
ICAM-1 (% of control) 
 
100  +  16 126   +   3 182  +  16 a,d 118   +  18
  
CCL2 (% of control) 100  +  15 
 
36    +   2     
 
156  +  58 b 
 
38   +   6  
CCL19  (% of control) 
 
100  +  16 99     +   13 207  +  57  82   +   13 c 
ATP (µM) 0.94 + 0.2 1.17 + 0.1 1.02 + 0.1 1.08 + 0.1 
 
 
1 Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water. bp < 0.05 
compared with TNFR1 -/- mice fed with plain water. cp< 0.05 compared with wild-type fructose fed mice. dp< 
0.05 compared with TNFR1 -/- fructose fed mice 
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3.1.3 Effect of fructose feeding on hepatic iNOS protein levels and lipid 
peroxidation in livers of TNFR1-/- mice 
Studies of our own group and those of other groups have shown that chronic fructose intake is 
associated with elevated levels of reactive oxygen species and lipid peroxidation (21, 59, 60) 
Therefore, hepatic iNOS levels and 4-hydroxynonenal adducts were determined in wild-type 
and TNFR1 -/- mice fed plain water or 30% fructose solution. Results are summarized in 
Figure 3. Hepatic iNOS protein levels were minimal and similar in wild-type and TNFR1 -/- 
mice fed water (Figure 3A). In contrast, iNOS protein levels of the liver were significantly 
higher by ~3.2-fold in fructose fed wild-type mice in comparison to water fed controls (Figure 
3A). A similar effect of fructose feeding on hepatic iNOS protein levels was also found in 
TNFR1-/- mice. In line with these findings levels of 4-hydroxynonenal protein adducts were 
significantly increased by ~3-fold in livers of both fructose fed wild-type mice and TNFR1 -/- 
mice (p<0.05 in comparison to their respective water controls) (Figure 3B). Conversely, 
levels of 4-hydroxynonenal protein adducts in the liver were minimal and remained similar in 
wild-type and TNFR1 -/- mice fed water (Figure 3B). 
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Figure 3 Effect of fructose feeding on iNOS protein levels and markers of lipid peroxidation in livers of 
TNFR 1-/- mice. (A) Representative photomicrographs of immunostaining of iNOS in liver sections (630x). (B) 
Photomicrographs of immunostaining of 4-hydroxynonenal protein adducts in liver sections (200x). (C&D) 
Densitometric analysis of the respective staining. Data are shown as means ± SEM (n = 4-6) and are normalized 
to percent of wild-type control. W – water; F – 30% fructose solution. ap < 0.05 compared with wild-type mice 
fed with plain water.  bp < 0.05 compared with TNFR1 -/- mice fed with plain water 
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3.1.4 Effect of fructose feeding on hepatic glucose metabolism and insulin 
signaling in TNFR 1-/- mice 
Results of our own group and those of other groups have indicated that alterations in glucose 
metabolism and hepatic insulin signalling may be associated with chronic fructose intake and 
induction of TNFα in the liver (21, 60, 67). Thus, in the present study markers of insulin 
resistance (e.g. RBP-4, Akt) as well as the expression of gluconeogenic enzyme PEPCK were 
determined in the livers of mice either fed with water or 30% fructose solution. Results are 
summarized in Figure 4. 
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Figure 4 Effect of fructose feeding on hepatic PEPCK mRNA expression, plasma levels of RBP4 and 
phosphorylation status of Akt in livers of TNFR1-/- mice. (A) PEPCK mRNA expression in the liver. (B) 
Representative photographs of western blots of phospho Akt and total Akt and quantitative analysis of blots. (C) 
Plasma RBP4 levels. Data are expressed as means ± SEM (n=4-6) and are normalized to percent of wild-type 
control. W – water; F – 30% fructose solution. a p < 0.05 compared with wild-type mice fed with plain water. b p 
< 0.05 compared with TNFR1 -/- mice fed with plain water. C p< 0.05 compared with wild-type fructose fed 
mice. d p< 0.05 compared with TNFR1 -/-  fructose fed mice. 
 
Hepatic PEPCK mRNA expression did not differ between water fed TNFR1-/- and fructose 
fed TNFR1-/- mice. However, in fructose fed wild-type mice PEPCK mRNA expression in 
the liver was lower by -~61% (p=0.06) in comparison to wild-type water controls (Figure 4 
A). As expected, phosphorylation of Akt was significantly lower by -~35% in livers of 
fructose fed wild-type mice in comparison to water fed wild-type mice. Interestingly, this 
effect of fructose feeding was not observed in the livers of TNFR1-/- mice, rather, the 
phosphorylation of Akt was higher and similar to that of water fed TNFR1-/- mice. (Figure 4 
B). In line with these findings, plasma RBP4 levels were significantly increased by +~1.6-fold 
in plasma of fructose fed wild-type mice in comparison to water fed wild-type mice. 
Conversely, similar effect of fructose feeding was not found in TNFR1 -/- mice  
+/+ -/- +/+ -/-
0
50
100
150
a,b,d
 W  W  F     F
R
B
P-
4 
co
nc
en
tr
at
io
n
(%
 o
f w
ild
-ty
pe
 c
on
tr
ol
)
C 
Results                                                                                                       
 
49 
3.1.5 Effect of fructose feeding on hepatic AMPK phosphorylation and 
lipogenesis in livers of TNFR1-/- mice  
Markers of hepatic lipid metabolism (e.g. SREBP-1, FAS and PAI-1) and AMPK, an enzyme 
involved in cellular homeostasis, were determined in the present study to examine if the 
protective effects of the deletion of TNFR1 were associated with alterations of any of the 
markers stated above. Results are summarized in Figure 5. Hepatic mRNA expression of 
SREBP-1 and FAS were similar in water fed controls regardless of substrains. However, 
chronic fructose feeding in wild-type mice was associated with a significant induction of 
SREBP-1 and FAS mRNA expression by ~3- and ~6-fold in comparison to water controls, 
respectively. In contrast, a similar effect of fructose feeding was not found in TNFR1 -/- mice, 
in livers of these animals SREBP-1 mRNA expression was at the level of controls fed plain 
water whereas expression of FAS was induced by ~3.5-fold in comparison to water controls 
(Figure 5 A & B). 
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Figure 5 Effect of fructose feeding on SREBP-1, FAS and PAI-1 mRNA levels as well as phosphorylation 
status of AMPK in livers of TNFR 1-/-mice. (A) SREBP-1, (B) FAS and (C) PAI-1 mRNA expression levels 
were normalized to 18S expression. (D) Representative photographs of western blots of phospho AMPK and 
total AMPK and quantitative analysis of blots. Data are expressed as means ± SEM (n=4-6) and are normalized 
to percent of wild-type control. W – water; F – 30% fructose solution. ap < 0.05 compared with wild-type mice 
fed with plain water.  bp < 0.05 compared with TNFR1 -/- mice fed with plain water. cp< 0.05 compared with 
wild-type fructose fed mice. dp< 0.05 compared with TNFR1 -/- fructose fed mice 
 
PAI-1 mRNA expression in the liver is known to be regulated through TNFα and insulin- 
dependent mechanisms, moreover, results of our own group and other groups indicate that 
hepatic PAI-1 mRNA expression is increased in patients with NAFLD ((19, 31, 68). In the 
present study, hepatic PAI-1 mRNA expression was minimal in water fed mice and did not 
differ between substrains (Figure 5 C). Conversely, in livers of fructose fed wild-type mice 
PAI-1 mRNA expression was significantly induced by ~2.2-fold in comparison to water fed 
controls (Figure 5 C). This effect of fructose feeding was markedly attenuated in the livers of 
TNFR1-/- mice (Figure 5 C). Phosphorylation of AMPK was similar in livers of water fed 
mice regardless of substrain as well as fructose fed wild-type mice. In contrast, 
phosphorylation of AMPK was increased in livers of fructose fed TNFR1-/- mice in 
comparison to the appropriate controls.  
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Taken together, results of aim 1 suggest that in fructose-induced NAFLD TNFα through its 
receptor TNFR1 may cause alterations in hepatic insulin signalling, lipid metabolism and 
induction of PAI mRNA expression. Therefore, it was further investigated to clarify if PAI-1 
is also a critical factor in the onset of fructose-induced hepatic steatosis.  
3.2 Studies in PAI-1-/- mice fed fructose 
As results of aim 1 suggested that chronic fructose feeding is not only associated with  
significant increase of triglycerides by +~5.8-fold in the livers of wild-type mice in 
comparison to controls (see section 3.1) but also with a significant increase in hepatic PAI-1 
mRNA expression by ~2.5-fold in comparison to controls (see Table 17). The role of PAI-1 in 
fructose-induced liver injury was further studied in PAI-1 knockout mice. 
3.2.1 Effect of fructose feeding on weight gain and liver to body weight 
ratio as well as hepatic PAI-1 mRNA expression in PAI-1-/- mice  
Body weight of mice was measured weekly. Results are summarized in Table 17. Absolute 
body weight was slightly higher in PAI-1-/- mice fed water than in controls; however, 
differences did not reach level of significance. Absolute weight gain did not differ between 
water fed controls.  
 
Table 17 Effect of fructose feeding on body weight and PAI-1 mRNA expression1 
 
 Water Fructose 
 Wild-type PAI-1-/- Wild-type PAI-1-/- 
Body weight (in g) 20.48±0.3 22.18±0.5 23.84±0.7 a 24.35±0.9 a 
Liver to body weight ratio (in %) 4.8±0.1 4.7±0.07  5.9±0.1 a,b 5.4±0.4 
Weight gain (g) 3.1±0.1 2.9±0.4 5.1±0.7 a,b 4.6±0.09 
PAI-1 (fold-induction) 2.2±0.4 n.d 4.7±0.9 a n.d 
1 Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water.  bp < 0.05 
compared with PAI-1 -/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose fed mice 
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When compared with their respective controls, absolute body weight gain of both fructose fed 
groups were significantly higher (wild-type: +~1.4g, PAI-1-/-: +~1.3g in comparison to 
respective controls, both p<0.05). In both fructose fed groups liver to body weight ratio was 
significantly higher than their respective controls (wild-type liver to body weight ratio: +~1-
fold; PAI-1-/- liver to body weight ratio: +~1-fold) (see Table 17) 
 
3.2.2 Effect of fructose feeding on liver steatosis in PAI-1-/-mice 
To determine the effect of the deletion of PAI-1 on liver damage in mice chronically exposed 
to fructose liver steatosis was assessed by H&E and Oil red O staining. Furthermore, 
triglyceride accumulation was also assessed in livers of PAI-1 -/- and wild-type mice either 
fed water, or water sweetened with 30% fructose for 8 weeks. Results are summarized in 
Figure 6. Triglyceride accumulation, lipid staining and pathological changes were minimal in 
water fed mice regardless of the strain. Conversely, hepatic triglyceride accumulation was 
increased by ~5.8-fold in livers fructose fed wild-type mice in comparison to appropriate 
controls whereas hepatic triglyceride accumulation was only increased by ~2-fold in PAI-1-/- 
mice exposed to fructose in comparison to PAI-1-/- mice fed water (Figure 6C). Similar 
results were also found in liver tissue stained with oil red O and H & E staining (Figure 6A & 
B).  
           
A
 
 
  
 
 
 
 
 
 
 
 
 
B 
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Figure 6 Effect of fructose feeding on hepatic lipid accumulation and histology in PAI-1-/- mice. (A) 
Representative photomicrographs of hematoxylin and eosin staining of liver sections. (B) Representative 
photomicrographs of oil red O staining of liver sections. (C) Quantitation of hepatic triglycerides content (n=5-
7). Data are expressed as means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water.  bp < 0.05 
compared with PAI-1-/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose fed mice.  
 
3.2.3 Effect of fructose feeding on endotoxin levels and TNFα protein 
concentration as well as insulin signaling in livers of PAI-1-/- mice 
Results of our own group have suggested that chronic fructose feeding in mice is associated 
with elevated plasma endotoxin levels as well as hepatic TNFα protein concentration (21). 
Therefore, in PAI-1-/- and wild-type mice fed fructose or water plasma endotoxin levels and 
hepatic TNFα protein concentration were determined. Results are summarized in Figure 7. 
Both endotoxin levels in portal plasma and TNFα protein concentration in the liver were 
minimal and did not differ between water fed mice regardless of strain (Figure 7A & B). 
Interestingly, chronic fructose feeding led to a significant increase of endotoxin levels in 
portal plasma as well as TNFα protein levels in the liver in both strains (Figure 7A & B). 
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Figure 7 Effect of fructose feeding on portal endotoxin and hepatic TNFα protein levels in PAI-1-/- mice. 
(A) Endotoxin levels in portal plasma (n=5-6). (B) Representative photographs of Western blots of TNFα and ß-
actin in liver tissue (C) quantitative analysis of blots (n=5). Data are expressed as means ± SEM. ap < 0.05 
compared with wild-type mice fed with plain water. bp< 0.05 compared with PAI-1-/- mice fed with plain water.  
 
In line with these findings, plasma RBP-4 and hepatic RBP-4 mRNA expression, both shown 
to be markers of insulin resistance (60, 61) were also found to be increased in fructose fed 
mice regardless of the strain (Table 18). In contrast, in water fed controls these markers did 
not differ and were minimal. In addition, hepatic GLUT-4 mRNA expression, recently shown 
to be associated with elevated PAI-1 levels in liver, was also determined (Table 20) (69). 
Hepatic GLUT-4 mRNA was markedly downregulated in mice fed chronically fructose 
regardless of strain (Table 18). Furthermore, markers of glucose homeostasis such as PEPCK 
and glucokinase were also determined. In livers of fructose fed wild-type mice PEPCK 
mRNA was significantly decreased in comparison to water fed wild-type mice (Table 18).  
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Table 18 Effect of fructose feeding on the markers of insulin resistance in the liver and in plasma1 
 Water Fructose 
 Wild-type PAI-1-/- Wild-type 
 
PAI-1-/- 
RBP 4 (µg/ml) 28.8±0.8 25.8±1.1 45.5±2.3 a,b 42±3.3 a,b 
RBP 4 mRNA 
(fold-induction) 
1.4±0.2 1.7±0.1 3.3±0.9 4.0±0.9 a 
GLUT-4 mRNA 
(fold-induction) 
315±50 273±106 6.0±0.7 a,b 4.5±1.2 a,b 
PEPCK mRNA 
(fold-induction) 
32.9±13 22.5±4.4 3.2±0.9 a 6.9±2.7 
Glucokinase mRNA 
(fold-induction) 
3.9±0.8 
 
4.9±0.6 
 
2.5±0.7 
 
8.7±0.7 a,b,c  
 
1 Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water.  bp < 0.05 
compared with PAI-1 -/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose fed mice. 
 
Interestingly, expression of glucokinase of mRNA in the liver was significantly higher in 
fructose fed PAI-1-/- mice than in all other groups (p<0.05). 
 
3.2.4 Effect of fructose feeding on c-Met signaling, lipoprotein synthesis 
and phosphorylation of Akt as well as BCL XL mRNA expression in livers 
of PAI-1-/- mice 
PAI-1 in various etiologies of hepatic steatosis (e.g. alcohol and endotoxin) has been 
shown to play a crucial role in the activation of the hepatic growth factor (HGF)/Met-
depending signaling cascades and subsequently  hepatic lipid metabolism (for overview see 
(34)).  
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Thus the effect of fructose feeding on cMet phosphorylation, expression of ApoB mRNA and 
activity of MTTP in livers of PAI-1-/- and wild-type mice was determined. Results are 
summarized in Figure 8. Phosphorylation of hepatic cMet was minimal in livers of water fed 
controls regardless of strain and fructose fed wild-type mice. In contrast, chronic feeding of 
30 % fructose solution in PAI-1-/- mice was associated with a significant increase of cMet 
phosphorylation by + ~4-fold in comparison to PAI-1-/- mice fed water (Figure 8A). In line 
with these findings ApoB mRNA expression was only found to be increased by +~2.3-fold in 
livers of fructose fed PAI-1-/- mice in comparison to PAI-1-/- mice fed water whereas in 
livers of fructose fed wild-type mice it remained at level of controls (Figure 8B). In addition, 
MTTP activity was also only found to be increased in livers of PAI-1-/- mice fed fructose 
by10% in comparison to PAI-1-/- mice fed water, however as the activity varied considerably 
between the animals differences did not reach to the level of significance (p=0.06). (Figure 
8C).  
 
Results of in vitro and in vivo studies have shown that phosphorylation of Akt may be 
regulated through cMet and the cMet dependent-Akt activation may modulate BCL-XL (an 
anti-apoptotic BCL-2 family protein) (70, 71). Therefore, phosphorylation of Akt and mRNA 
expression of BCL-XL in livers of fructose and water fed mice were determined. Chronic 
feeding of 30% fructose solution significantly decreased phosphorylation levels of Akt in 
livers of fructose fed wild-type mice in comparison to water controls (Figure 8D). 
Interestingly, this effect of fructose feeding was not found in livers of fructose fed PAI-1-/- 
mice (Figure 8D). Similar results were also found for BCL-XL mRNA expression in livers of 
wild-type and PAI-1-/- mice fed. (see Table 19). 
 
Table 19 Effect of fructose feeding on BCL-XL mRNA expression1 
 Water Fructose 
 Wild-type PAI-1-/- Wild-type 
 
PAI-1-/- 
BCL-XL mRNA 
(fold-induction) 
   5.9±0.9    2.9±0.6    1.8±0.2 a    6.8±1.7 c 
1 Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water. cp< 0.05 
compared with wild-type fructose fed mice. 
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Figure 8 Effect of fructose feeding on phosphorylation of cMet, Akt protein and ApoB mRNA expression 
as well as MTTP activation in livers of PAI-1-/- mice. (A) Representative photographs of Western blots of 
phospho c-Met, total c-Met and quantitative analysis of blots (n=4) (B) ApoB mRNA levels normalized to ß-
actin expression (n=5) (C) MTTP activity (n=5) and (D) representative photographs of Western blots of phospho 
Akt and total Akt and quantitative analysis of blots (n=5). Data are expressed as means ± SEM. ap < 0.05 
compared with wild-type mice fed with plain water.  bp < 0.05 compared with PAI-1-/- mice fed with plain 
water.  cp< 0.05 compared with wild-type fructose fed mice.  
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Effect of HGF on PAI-1-stimulated AML 12 cells  
The role of PAI-1 and HGF in modulating triglyceride export in the liver was further 
investigated in a cell culture model (e.g. AML12 cells = model of murine hepatocytes). AML 
12 cells were challenged with PAI-1 in the presence or absence of HGF as described in 
section 2.2.4. Results are summarized in Figure 9. HGF alone had no effect on triglyceride 
content and MTTP activity in AML12 cells (Figure 9 A&B). Conversely, stimulation of cells 
with PAI-1 resulted in a significant decrease of MTTP activity in comparison to naïve cells 
(~81%). In line with these findings, triglyceride concentration was significantly increased in 
these cells (~+ 10-fold in comparison to naïve cells). Interestingly, when cells were treated 
with HGF while concomitantly being challenged with PAI-1, MTTP activity remained at the 
level of naïve cells and cells did not accumulate triglycerides (Figure 9 A&B). 
  
 
 
Figure 9 Effect of PAI-1 on triglyceride accumulation and MTTP activity in AML12 cells. (A) Triglyceride 
accumulation and (B) MTTP activity. Data are expressed as means ± SEM (n=3). ap < 0.05 compared with naïve 
cells. bp < 0.05 compared with HGF treated cells. cp< 0.05 compared with PAI-1 treated cells.  
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3.2.5 Effect of fructose feeding on hepatic NKT cells in PAI-1-/- mice 
Recently it has been shown that MTTP plays a crucial role in the lipidation of the CD1d 
receptor, a receptor involved in the regulation of NKT cell viability (72, 73). Therefore, 
expression of CD1d and markers of iNKT cells as well as iNKT cell activation in livers of 
PAI-1-/- and wild-type mice fed with water or fructose were determined. Results are 
summarized in Table 20 and Figure 10. In livers of PAI-1-/- mice CD1d mRNA expression 
was markedly higher regardless of feeding. (see Table 20). 
 
Table 20 Effect of fructose feeding on expression of CD1d, IL-15,and IFN γ in livers of PAI-1-/- and wild-
type mice1 
 Water Fructose 
 Wild-type PAI-1-/- Wild-type 
 
PAI-1-/- 
CD1d (fold-induction) 6.1±0.6 
 
9.5±1.8 4.5±1.1 b 11.3±0.7 a,c 
IL-15 (fold-induction) 3.1±0.3 3.2±0.9 4.5±0.9 
 
7.4±1.2 a,b 
 
IFNγ (fold-induction) 4.3±1.0 
 
6.2±1.6 
 
2.3±0.6 
 
10.2±1.2 a,c 
 
1Values represent means ± SEM. ap < 0.05 compared with wild-type mice fed with plain water.  bp < 0.05 
compared with PAI-1 -/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose fed mice. n.d= 
not detectable 
Furthermore, iNKT cell surface markers CD3ε and NK1.1 were also determined in the liver 
and the results are summarized in Figure 10. Expression of CD3ε and NK1.1 were found to be 
increased in PAI-1-/- mice regardless of feeding (CD3ε: +~5.7-fold in comparison to wild-
type water controls, +~6.2-fold in comparison to wild-type fructose fed mice. NK1.1: +~4-
fold in comparison to wild-type water controls, +~3.5-fold in comparison to wild-type 
fructose fed mice) In line with these findings, hepatic CD3ζ staining was also found to be 
increased in PAI-1-/- mice regardless of additional treatments (Figure 10). In contrast, 
markers of iNKT cells activation (e.g. interleukin 15 (IL-15) and interferon γ (INFγ)) was 
only found to be significantly increased in fructose fed PAI-1-/- mice (see Table 20).  
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Figure 10 Effect of PAI-1 deletion on iNKT cell markers in livers of fructose fed mice. (A) Representative 
photographs of CD3ζ staining of liver sections; brown stained parts marked with arrows indicate CD3ζ positive 
cells (B) CD3ε mRNA levels normalized to 18S expression (n=5) (C) NK1.1 mRNA levels normalized to 18S 
expression (n=5). Data are expressed as means ± SEM. ap < 0.05 compared with wild-type mice fed with plain 
water.  bp < 0.05 compared with PAI-1-/- mice fed with plain water.  cp< 0.05 compared with wild-type fructose 
fed mice.  
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3.3 Studies in human liver samples 
The results of aim 1 and 2 published before in Kanuri et al.2010 (74) and Kanuri et al. 2011 
(75) suggest that PAI-1 may be a critical factor in the onset of fructose-induced steatosis in 
mice through mechanisms involving a suppression of the compensatory up regulation of lipid 
export necessary to protect the liver from the increased amount of lipids resulting from a 
chronic dietary intake of fructose. In addition, the data also suggest that PAI-1 may also be 
involved in modulating CD1-reactive NKT cells in the liver. Therefore, it was further 
investigated in human subjects whether similar mechanisms are also involved in the 
development of NAFLD. Specifically, to determine if PAI-1, insulin signaling and iNKT cells 
are also altered in livers of human with NAFLD.  
 
3.3.1 Dietary intake and physical activity of human subjects 
Total intake of carbohydrates, fat, protein and the total energy intake did not differ between 
the controls and NAFLD subjects (Table 21). However, physical activity was less frequent in 
NAFLD subjects (50%) than in controls (100%). Total glucose and sucrose consumption were 
higher between NAFLD subjects and controls, however, as the intake varied considerably 
between the subjects the differences did not reach to the level of significance. Total fructose 
intake, derived from free fructose and sucrose, was significantly higher by ~10 g/d in subjects 
with NAFLD than in controls (see Table 21).  
Table 21 Nutritional intake of NAFLD subjects and controls1 
 Control NAFLD patients 
n 6 12 
Energy kj/d 9106 + 670 9387 + 461 
Protein g 79 + 6 88 + 3 
% Energy 15 + 0.4 16 + 0.7* 
Fat g 87 + 10 89 + 7 
% Energy 40 + 10 59 + 12 
Carbohydrates g 256 + 15 253 + 14 
% Energy 49 + 3 49 + 1 
Glucose2, g/d 37 + 4 42.8 + 4.3 
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Sucrose, g/d 48.3 + 7.2 57.3 + 6.3 
Fructose3, g/d 41.0 + 3.2 51.5 + 5.2* 
Alcohol, g/d 6.5 + 2.3 4.0 + 1.2 
 
1 Values are means + SEM. *Different from controls, P<0.05. 2 Glucose intake derived from free glucose and 
sucrose . 3Fructose intake derived from free fructose and sucrose. (Table adapted from Thuy et al. 2008) 
 
3.3.2 Lipid peroxidation in human subjects with NAFLD 
As results of our own group and those of other groups in mice suggested that NAFLD in 
rodents is associated with an increased formation of reactive oxygen species (ROS) and lipid 
peroxidation (21, 57, 60) 4-hydroxynonenal adducts were determined in the livers of human 
NAFLD subjects and controls. Levels of 4-hydroxynonenal adducts in livers of human 
NAFLD subjects were significantly higher by ~2-fold in comparison to controls (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Hepatic 4-hydroxynonenal (4-HNE) protein adducts staining in controls and NAFLD patients 
(A) Representative photographs of 4-HNE protein adducts staining; brown stained parts indicate 4-HNE protein 
adducts staining (B) densitometric analysis of the staining.*p< 0.05 compared with controls (n=6 controls; n=8 
NAFLD patients).  
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3.3.3 Hepatic IRS-1 mRNA expression and PAI-1 protein levels in human 
subjects with NAFLD 
Results of animal studies have revealed that NAFLD in rodents is associated with an 
induction of expression of PAI-1 and altered insulin signaling (74, 75). Therefore, hepatic 
proteins levels of PAI-1 and IRS-1 mRNA were determined in human NAFLD subjects and 
controls to investigate whether similar mechanisms are also involved in the development of 
NAFLD in humans. Hepatic PAI-1 protein concentration localized to hepatocytes was 
significantly higher by ~2.4-fold in human NAFLD subjects in comparison to controls. In 
contrast, expression of IRS-1 mRNA was significantly lower by ~80 % in livers of NAFLD 
patients in comparison to controls (Figure 12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Hepatic PAI-1 protein levels and IRS-1mRNA expression in NAFLD patients (A) Representative 
photographs of PAI-1 staining; brown stained parts marked with arrows indicate PAI-1 staining and (B) 
densitometric analysis of the staining (n=6 controls; n=8 NAFLD patients). (C) IRS-1 mRNA expression 
normalized to ß-actin (n=6 controls; n=11 NAFLD patients).  *p< 0.05 compared with controls. **p< 0.001 
compared with controls. 
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3.3.4 Hepatic mRNA expression of cMet, BCL-2l, MTTP and CD1d in 
human subjects with NAFLD 
Hepatic cMet mRNA expression was significantly lower in NAFLD patients in comparison to 
controls. In line with these findings mRNA expression of BCL 2l was considerably lower by 
~71% in NAFLD patients in comparison to controls (Figure 13 A&B). However, no 
differences were found in the mRNA expression of MTTP and CD1d between the livers of 
NAFLD patients and those of controls (Figure 13 C&D). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Hepatic mRNA expression of c-Met, BCL 2l, MTTP and CD 1d in NAFLD patients (A) c-Met 
mRNA expression, (B) BCL2l mRNA expression, (C) MTTP mRNA expression and (D) CD1d mRNA 
expression normalized to ß-actin. (n=6 controls; n=11 NAFLD patients). *p< 0.05 compared with controls. **p< 
0.001 compared with controls. 
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3.3.5 Hepatic accumulation of iNKT cells and mRNA expression of IL-4 
and IL-15 in NAFLD patients 
In NAFLD patients number of iNKT cells in the liver was significantly increased in 
comparison to controls (Figure 14 A&B). Contrary to the increased number of iNKT cells, 
expression of iNKT cell markers such as IL-4 and IL-15 were significantly lower in livers of 
patients with NAFLD when compared with controls (Figure 14 C&D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Hepatic CD3ζ staining and mRNA expression of IL-4 and IL-15 in NAFLD patients (A) 
Representative photographs of CD3ζ staining of liver sections (brown stained parts marked with arrows indicate 
CD3ζ positive cells) (B) Densitometric analysis of the staining (n=6 controls; n=8 NAFLD patients). (C) IL-4 
mRNA expression and (D) IL-15 mRNA expression in the liver normalized to ß-actin. (n=6 controls; n=11 
NAFLD patients). *p< 0.05 compared with controls. **p< 0.001 compared with controls. 
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4 Discussion 
Non-alcoholic fatty liver disease with its clinical spectrum spanning from simple fatty liver to 
cirrhosis is by now one of the major cause for liver related mortality worldwide. The 
consumption of fructose has enormously increased in the US and in Europe over the last three 
decades, paralleling the prevalence of obesity and type-2-diabetes (35, 36, 76). Emerging 
evidences suggest that consumption of a carbohydrate rich diet and herein particularly a diet 
rich in fructose may also be a risk factor in the development of NAFLD in humans (19, 55, 
77). Indeed, results of intervention studies in humans and animals suggest that a diet rich in 
fructose can result in dyslipidemia, hepatic insulin resistance and fatty liver disease (21, 57, 
59, 78). Results of our own group indicate that besides the ‘de novo lipogenesis’ (also see 
chapter 1.2) caused by the metabolism of fructose, one of the major events in fructose-
induced NAFLD involves the activation of the TLR 4 signalling cascade in the liver due to an 
increased intestinal translocation of endotoxin from the gut (21, 60). Furthermore, this 
increased intestinal translocation of bacterial endotoxin from the intestine to the portal vein 
due to chronic fructose intake was associated with elevated formation of reactive oxygen 
species and tumor necrosis factor (TNF) α expression in the liver (21). Results of animal 
studies have repeatedly shown that an increased expression of TNF α is linked with the 
development of NAFLD (27, 28, 79). 
 In models of alcoholic liver disease (ALD) the damaging effect of TNF α was associated with 
an elevated expression of hepatic PAI-1 whereas the genetic deletion of TNFR 1 or PAI-1 was 
associated with a protection against ALD (32). Results of our own group (19) but also other 
group (31) suggest that PAI-1 expression is also involved in the development of NAFLD in 
humans. It has further been suggested by the results of animal studies that PAI-1 is a 
modulator of hepatic lipid transport in acute and chronic alcoholic liver disease (ALD)(32). 
Taken together these results suggest that PAI-1 may be a critical factor in the pathogenesis of 
ALD.  
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However, if PAI-1 is also critically involved in the onset of NAFLD and if so what the under- 
lying mechanisms involved in the induction of PAI-1 in the liver has not yet been determined. 
Therefore, the main aim of the PhD thesis was not only to investigate the role of TNF α and 
it’s receptor TNFR1 in the induction of PAI-1 in mouse models of NAFLD as well as in 
humans but also to further clarify the role of PAI-1 in the development of NAFLD. 
4.1 TNFR 1-/- mice are protected from fructose-induced 
steatosis 
Several studies have suggested a role of TNFα in the pathogenesis of NAFLD. For instance, 
Crespo et al., found elevated levels of TNFα mRNA and TNFα receptor p55 protein in 
NAFLD patients (80). In rodent studies it was shown that administration of TNF antibodies to 
ob/ob mice fed high fat diet improved hepatic steatosis, insulin sensitivity and inflammation 
in the liver (81). However, if TNFα is also a critical factor in the development of fructose-
induced NAFLD and if the effects of TNFα are mediated through it’s receptor has not been 
determined. In the present study, TNFR 1-/- mice and wild-type mice were chronically fed 
30% fructose solution for 8 weeks to test the hypothesis that TNFα through its receptor 1 
plays a casual role in the onset of fructose-induced NAFLD. In TNFR 1-/- mice, hepatic 
steatosis was markedly less pronounced in fructose fed mice in comparison to wild-type mice. 
This protective effect was associated with a decreased hepatic inflammation (e.g. infiltrating 
neutrophils as well as expression of ICAM-1, CCL2 and CCL19) in fructose fed TNFR 1-/- 
mice. In contrast, no differences were found between fructose fed groups in regards to 
inducible nitric oxide synthase (iNOS) protein, 4-hydroxynonenal (4-HNE) adducts and ATP 
levels. In line with our findings, recent studies of other groups have also shown that the 
deletion of TNFR 1 decreased high fat diet induced hepatic lipid accumulation and 
inflammation (82). These results suggest that TNFα through its receptor TNFR 1 may not 
only regulate lipid accumulation but also mediating an induction of chemokine secretion and 
adhesion molecules (e.g ICAM 1) in the liver. Indeed, studies have shown before that defect 
in TNFR 1 signalling downregulated hepatic ICAM-1 expression thereby decreasing 
inflammation (27). 
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Results of our own group suggest that concomitant antibiotic treatment or deletion of TLR-4 
(endotoxin receptor) in fructose fed mice decreased 4-HNE (a marker for ROS formation) and 
an induction of iNOS levels (21, 60, 83). In line with these findings, iNOS expression but also 
4HNE protein adducts levels were markedly high in livers of fructose fed mice regardless of 
strain. This elevated induction of iNOS and 4HNE protein addcuts was seemed to be resulting 
from increased translocation of intestinal bacterial endotoxins. Hepatic ATP levels were 
shown before by Latta M et al. to be depleted after an acute intravenous exposure of fructose 
in mice whereas in this study chronic oral exposure was not associated with a depletion of 
hepatic ATP levels in fructose fed mice (66). Differences between the results of the present 
study and those of Latta M et al. may have resulted from the different feeding/exposure 
patterns. Furthermore, earlier in vitro studies of Latta M et al. have shown that fructose at a 
concentration of 50mM did not deplete ATP levels in human HepG2 or murine Hepal-6 
hepatoma cells (84). Taken together, it cannot be ruled out that fructose may add to the 
development of NAFLD through its insulin-independent metabolism or through alterations of 
the bioavailability of ATP but also through increased bacterial endotoxin and intestinal 
permeability thereby activation of Kupffer cells associated with iNOS induction and reactive 
oxygen species formation and an induction of TNFα.  
 
TNFR1 mice are protected from fructose-induced alterations of insulin 
signalling and lipid metabolism 
Results of animal and human studies suggest that insulin resistance may also be a 
critical factor in the development of NAFLD (67). Furthermore, TNFα has been shown before 
not only to promote insulin resistance but also to be activated by insulin resistance via 
activation of IKKβ (85). Therefore, in the present study markers of insulin resistance such as 
phosphorylation of Akt and plasma RBP-4 levels were determined. Chronic fructose feeding 
in wild-type mice was associated with an altered phosphorylation status of Akt in the liver as 
well as plasma RBP-4 levels in wild-type mice whereas this effect was not found in fructose 
fed TNFR1-/- mice, suggesting that TNFα though it’s receptor may play a critical role in 
fructose-induced insulin resistance.  
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These results are in accordance with results of our earlier study where we showed that 
hepatic phospho Akt levels as well as plasma RBP-4 levels were altered in fructose fed mice 
(60). Interestingly, expression of gluconeogenic enzyme PEPCK mRNA was found to be 
significantly lower in TNFR1-/- mice regardless of feeding in comparison to wild-type 
controls, suggesting that wild-types and TNFR 1-/- may have a differential regulation of 
PEPCK or even gluconeogenesis, These results indicate an adaptive mechanism of TNFR 1-/- 
mice to the lack of inhibitory effect of TNFα on PEPCK. Indeed Yan et al. showed in in vitro 
experiments that PEPCK expression was inhibited by TNFα (86). Furthermore, recent studies 
of Lim JH et al. have shown that an overexpression of PEPCK is associated with 
mitochondrial dysfunction, a response to endoplasmic reticulum (ER) stress (87). 
Furthermore, AMPK, which is known as energy sensor that regulates cellular metabolism, has 
been shown to regulate hepatic lipogenesis through down-regulation of SREBP 1c (88, 89). In 
line with these findings SREBP1c, FAS and PAI-1 were only induced in livers of wild-type 
mice whereas in livers of TNFR1 mice phospho AMPK was induced. These results suggest 
that TNFα plays a vital role in hepatic lipid metabolism through suppression of AMPK which 
may down regulate SREBP 1c. Moreover, expression of PAI-1, which has been lately linked 
to hepatic lipid export also see chapter 4.2 and 3 (34) and which is also known to be regulated 
by insulin-dependent mechanism, was found to be induced in fructose fed wild-type mice. 
These findings are in accordance with results of Cai D et al.(85) where it was shown that 
TNFα though activation of NFĸB may regulate the inflammatory mediators like PAI-1. Taken 
together, these data suggest that TNFα through its receptor TNFR1 is at least partly 
responsible for fructose-induced insulin resistance thereby suppressing AMPK and inducing 
lipogenesis as well as PAI-1 expression.  
 
4.2 PAI-1 -/- mice are protected from the development of hepatic 
steatosis 
 
The findings of aim 1 and herein particularly the TNFα dependent induction of PAI-1 but also 
results of studies on the mechanisms of alcohol-induced liver damage (32) suggest that PAI-1 
may be a critical factor in the development of liver damage . 
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In the present study, to further test if PAI-1 is a critical factor in the development of fructose-
induced NAFLD, PAI-1-/- mice and wild-type mice were chronically fed 30% fructose 
solution for 8 weeks. Chronic fructose feeding induced fat accumulation in the livers of wild-
type mice whereas fat accumulation was reduced to ~-50% in fructose fed PAI-1 -/- mice, 
despite similarly elevated endotoxin levels in portal plasma and TNFα protein concentration 
in the liver of both the strains. These data suggest that PAI-1 may be an essential factor in 
mediating the effects of the increased translocation of bacterial endotoxin and the subsequent 
activation of Kupffer cells in livers of fructose fed mice.  
 
On the other hand, PAI-1 has also lately been linked to hepatic lipid export and has shown to 
inhibit urokinase-type plasminogen activator (uPA), to modulate the activation of 
prohepatocyte growth factor (proHGF) to HGF (for review see (34)). HGF through its 
receptor cMet has been shown to stimulate the MTTP-dependent lipoprotein secretion in 
hepatocytes (32, 90, 91). In support of these results, it has been shown before that acute 
alcohol exposure is associated with an upregulation of cMet phosphorylation, MTTP activity 
and ApoB concentration in PA1-/- and TNFR1-/- mice (32). Indeed, in the present study 
phosphorylation of cMet, ApoB mRNA and MTTP activity was increased in PAI-1-/- mice 
fed with fructose whereas in wild-type mice fed with fructose all these parameters remained at 
the level of controls. These results were further bolstered by in vitro studies (e.g. AML-12 
cells=model of hepatocytes) in which the treatment of hepatocytes (e.g. AML 12 cells) with 
PAI-1 caused triglyceride accumulation and reduction of MTTP activity whereas this effect of 
PAI-1 was attenuated by HGF treatment. Taken together, these results suggest that through an 
inhibition of uPA PAI-1 may alter the activation of pro HGF to HGF, which in turn cannot 
bind to its receptor cMet thereby suppressing an upregulation of MTTP, which results in an 
accumulation of triglycerides in hepatocytes that are no longer transported out of the cells via 
ApoB/VLDL. On the contrary, deletion of PAI-1 may facilitate the cell to increase VLDL 
synthesis and to transport greater amounts of triglycerides out of the cell. 
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PAI-1 regulates Akt and apoptosis in the livers of fructose-induced NAFLD 
mice 
 
 A loss of insulin sensitivity has been claimed to be a key factor in the development of 
NAFLD (for overview see (92)).Furthermore, it has been demonstrated in animal studies that 
chronic intake of fructose can cause insulin resistance (60, 61). Indeed, in the present study 
chronic fructose feeding was associated with markedly altered all parameters of insulin 
resistance in wild-type mice (e.g. RBP-4 plasma concentration, GLUT-4, PEPCK, RBP-4 and 
glucokinase mRNA expression as well as phosphorylation status of Akt in the liver). 
Interestingly, chronic fructose feeding also increased RBP-4 levels and decreased hepatic 
GLUT-4 and PEPCK mRNA expression in PAI-1 -/- mice suggesting that these mice also had 
impaired insulin signalling or were insulin resistant. However, contrary to the findings in 
livers of fructose fed wild-type mice phosphorylation status of Akt was similar to that of 
controls fed water in livers of PAI-1-/- mice. These results suggest that PAI-1 may alter 
phosphorylation of Akt. 
Indeed, cMet has shown to be regulated through PAI-1 dependent signalling pathways 
may play different roles in cellular functions. For instance, it has been shown that cMet is 
involved in regulation of PI3K/Akt signalling cascade (70, 93) and HGF-cMet-Akt dependent 
pathways were shown to modulate the expression of anti-apoptotic BCL2 protein BCL-XL 
(71). In line with these findings, expression of BCL-XL was upregulated in livers of fructose 
fed PAI-1-/- mice, whereas a similar effect was not found in fructose fed wild-type mice. 
These findings are in line with the in vitro studies of Bu R et al., where it was shown that 
cMet activates anti apoptotic markers (e.g BCL XL) through phosphorylation of Akt (94). 
These findings are also supported by the results of Balsara RD et al. where it was shown that 
PAI-1 may regulate cell survival through modulation PI3K/Akt pathway in endothelial cells 
(95). Furthermore, a similar effect was also found for mRNA expression levels of 
glucokinase. Indeed, similar to Akt, it has been suggested by the results of other groups before 
that glucokinase expression is not solely regulated by insulin (96). For instance, the results of 
García-Ocaña et al. suggest that HGF/ c-Met signalling cascades may also be involved in the 
regulation of glucokinase expression (96).  
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Taken together, our results suggest that fructose fed PAI-1-/- mice are protected 
against the onset of fructose-induced liver steatosis despite displaying signs of insulin 
resistance (e.g. elevated plasma and hepatic mRNA RBP-4 levels and decreased GLUT-4 and 
PEPCK expression in the liver). Furthermore, PAI-1 deletion may protect the liver from 
impaired PI3K/Akt signalling cascade occurred due to fructose intake thereby also promoting 
an anti-apoptosis status in the liver. 
 
Protection of PAI-1-/- mice from fructose-induced steatosis is associated 
with an induction of markers of iNKT cell activation 
MTTP, besides being a key enzyme in the regulation of hepatic lipid export via 
VLDL, is also necessary for the transfer of lipids to the iNKT cell receptor CD1d (73, 97). 
Indeed, in an in vitro assay, it was shown that MTTP may transfer phospholipids to CD1d 
suggesting a vital role of MTTP in lipidation of CD1d and its lipid antigen presentation to 
CD1d-restricted NKT cells (73, 98). Furthermore, it was also shown that MTTP gene deletion 
or inhibition may cause significant decrease in CD1d antigen presentation to iNKT cells (73, 
97). Recently it was shown that iNKT cells may be involved in metabolic control due to their 
striking ability to sense lipids (99). For instance, results of Elinav et al., have shown that 
adoptive transfer of NKT lymphocytes protected ob/ob mice from steatohepatitis and glucose 
intolerance (100). Additionally, it was suggested that in mouse models of NAFLD (e.g diet-
induced NAFLD and ob/ob mice) the progression of the disease was related to a marked 
decrease in CD1d reactive hepatic iNKT cells (101, 101, 102). Recently it was shown by 
Kremer et al., that in the steatotic liver Kupffer cells contribute to depletion of iNKT cells 
(103). In the present study, regardless of feeding, PAI-1-/- mice has increased expression of 
hepatic CD 1d as well as iNKT cells markers (e.g CD3ε and NK1.1). Conversely, the iNKT 
cell activation markers (e.g. IL 15 and IFNγ) were only found to be increased in the livers of 
fructose fed PAI-1-/- mice. In line with earlier findings of other groups (101, 101) the results 
of the present study also suggest that an upregulation of MTTP due to a PAI-1 deletion is 
associated with higher number of active CD1d restricted iNKT cells.  
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Furthermore, these data also suggest that a PAI-1 deletion in mice may also increase 
the expression of cytokines like IL-15 from NKT cells, which has recently been shown to 
contribute for liver regeneration in damaged livers (104). In regards to IFNγ expression, it 
was recently shown that iNKT cells may express untranslated cytokines mRNAs (e.g. IFNγ) 
in unchallenged or healthy state in mice (105, 106) suggesting that PAI-1 deletion may 
promote an unstimulated or unchallenged (e.g. healthy) environment in the livers of mice. 
Altogether, the results of aim 2 suggest that PAI-1 plays a vital role in the onset of fructose-
induced hepatic steatosis through suppression the upregulation of hepatic lipid export, which 
is an essentially adaptive mechanism to protect liver from increased amount of lipids occurred 
due to excessive consumption of fructose. Furthermore, the data also suggests that through 
modulating lipid export, PAI-1 is indirectly involved in modulating CD1 reactive iNKT cells 
in the liver.  
 
4.3 Human studies 
PAI-1 and markers of insulin signaling in livers of human patients with 
NAFLD 
 
The third aim of this PhD thesis was to further investigate if the alterations found in 
animal models of NAFLD (e.g. increased lipid peroxidation, impaired insulin signalling and 
alterations of iNKT cells as well as activation markers) are also found in livers of patients 
with NAFLD. Indeed, levels of 4-HNE protein adducts were markedly higher in the livers of 
NAFLD patients in comparison controls suggesting that the formation of ROS was elevated in 
NAFLD patients. These findings are line with the results of our own group where it was 
shown that chronic fructose intake in mice is associated with higher levels of portal endotoxin 
and lipid peroxidation in the liver (21, 60, 61). Furthermore, results of Thuy et al. indicated 
that NAFLD patients have higher endotoxin levels in peripheral blood in comparison to 
controls (19). Results of Seki et al. indicated that concentration of 4-HNE protein adducts 
were significantly higher in NAFLD patients even at early stages (steatosis) in comparison 
controls (107).  
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Furthermore, it has also been shown that markers of ROS such as plasma levels of 
malondialdehyde (MDA) and thiobarbituric acid reactive substances assay (TBARS) were 
significantly higher in NAFLD patients in comparison to controls (108). Results of in vitro 
and in vivo studies have shown that endotoxin may increase the formation of ROS, which is a 
trigger for the redox sensitive receptor NFĸB and subsequently release the TNFα (for review 
see (83)). In addition, several in vivo and in vitro studies have shown that increased levels of 
TNFα may induce insulin resistance (109). Results of aim 1 of this thesis have indicated that 
TNFα through it’s receptor TNFR 1 may add to the development of insulin resistance. 
Furthermore, results of Li et al. have shown that stimulation of Hep G2 cell lines (cells being 
a model of hepatocytes) with TNFα inhibit phosphorylation of IRS-1 subsequently leading to 
insulin resistance (110). Furthermore, in settings of alcohol-induced liver damage TNFα has 
been shown to modulate PAI-1 expression in insulin-dependent manner (32). In the present 
study, enhanced lipid peroxidation was associated with a decreased expression of IRS-1 
mRNA and increased PAI-1 protein levels being localized to hepatocytes, suggesting that 
insulin signalling may be impaired in NAFLD patients despite no elevated fasting glucose 
levels. The lower IRS-1 mRNA expression observed in the livers of NAFLD patients in the 
present study was in contrast with the results of Gracia Monzon et al. who observed in the 
livers of NASH patients (111). The discrepancy between our study and that of Gracia Monzon 
et al. study may be due to the environmental and genetic factors. However, previous studies 
have shown that insulin resistance was independent of histological severity in livers of HCV 
patients (112, 113) suggesting that impairment of hepatic insulin signalling might be an early 
event at NAFLD. The results of PAI-1 protein levels are in accordance with our previous 
findings where we found an increased PAI-1 mRNA expression in livers of NAFLD patients 
in comparison to controls (19). Interestingly, staining for PAI-1 concentration revealed that 
PAI-1 was primarily confined to hepatocytes. Furthermore, results of Alessi et al. indicate a 
strong correlation between steatotic liver and plasma PAI-1 levels in rodents as well as in 
humans (31). Taken together, the results of this aim suggest that in livers of humans with 
NAFLD formation of ROS, insulin resistance and formation acute phase protein PAI-1 are 
increased similar to the findings of animal models of fructose-induced NAFLD. 
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cMet signalling in human NAFLD patients 
 Studies in animals and humans have suggested that in addition to an increased 
de novo lipogenesis, an impaired hepatic lipid export may also contribute to lipid 
accumulation in NAFLD (31, 32, 75). Indeed, studies of our own group have suggested that 
PAI-1 may impair hepatic lipid export through altering the activation of HGF-cMet signalling 
cascade (32, 75). Indeed, results of aim 2 have shown that hepatic cMet phosphorylation is 
elevated in fructose fed PAI-1-/- mice. In addition, it was also shown that treating rat 
hepatocytes with HGF resulted in an activation of cMet and subsequently stimulated 
lipoprotein secretion (114). In the present study mRNA expression of cMet was markedly 
lower in livers of NAFLD patients. Moreover, the anti-apoptotic protein BCL-2l, a 
downstream target of cMet (71) was also found to be lower in livers of NAFLD patients 
suggesting that NAFLD patients may have higher levels of apoptosis. Taken together, these 
results suggest that in livers of patients with NAFLD cMet signalling may be impaired 
thereby leading to apoptosis similar to the findings of animal models of fructose-induced 
NAFLD. 
 
iNKT cells in human NAFLD patients 
 In the present study expression of MTTP and CD1d did not differ between controls 
and NAFLD patients. This inconsistency with our results of animal studies may be due to 
analysis of mRNA expression in humans whereas analysis of protein levels or activity in 
animal studies. Indeed, studies of others suggest that MTTP activity is not merely regulated at 
the level of mRNA expression but rather through half-life of MTTP mRNA larger subunit 
(115). However, as tissue samples in the present study were limited it was not possible to 
determine if MTTP activity was altered in the livers. This will have to be addressed in future 
studies. Hence, it cannot be precluded that NAFLD in humans, too, may be associated with 
impaired lipid export from the liver. Furthermore, another controversial finding to rodent 
models of NAFLD was that the numbers of CD3ζ positive cells (iNKT cells) was markedly 
higher in NAFLD patients in comparison to controls. In line with our findings in humans 
Tajiri et al. have shown that in NASH patients number of iNKT cells was markedly higher 
(116).  
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Furthermore, the results of Syn et al., suggest that an elevated number of iNKT cells in human 
NASH patients may be a feature of cirrhosis (117). These data may suggest that the patients in 
the present study might be on the verge to develop the next stage of liver disease (e.g. 
cirrhosis). However, the expression of iNKT cell markers (e.g. IL 4 and IL-15) was lower in 
NAFLD patients, suggesting that iNKT cells may not be active. Taken together, these results 
suggest that similar to rodents NAFLD in humans is associated with altered iNKT cell 
numbers. However, the implication of the findings needs to be addressed in future studies. 
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4.4 Conclusion and outlook  
Taken together, the results of the present studies suggest that TNFα through its receptor 
TNFR1 is casually involved in the development of fructose-induced NAFLD in mice. 
Furthermore, the results indicate that TNFα through its receptor seems to be involved in the 
development of hepatic insulin resistance and may thereby add to alterations found in 
lipogenesis as well as the induction of hepatic PAI-1 expression associated with fructose-
induced NAFLD. Indeed, in the present thesis it was shown in studies with PAI-1-/- mice that 
PAI-1 may be a critical factor in the onset of fructose-induced steatosis through mechanisms 
involving suppression of the up-regulation of lipid export necessary to protect the liver from 
the increased amount of lipids resulting from chronic dietary intake of fructose. The present 
study further suggest that PAI-1 may modulate PI3K/Akt signaling and CD 1 reactive iNKT 
cells. In Figure 15 the possible mechanism involved in the development of fructose-induced 
NAFLD in rodents are summarized. The results of aim 3 of this thesis suggest that similar to 
the alterations found in mouse models of fructose-induced NAFLD, NAFLD in humans is 
also associated with increased ROS production, impaired insulin signaling leading to PAI-1 
induction in hepatocytes. Furthermore, similar to rodents hepatic lipid export was also altered 
in patients with NAFLD. Altogether, the present study suggests that consumption of 
carbohydrates rich diet here in particularly fructose may lead to the development of onset of 
NAFLD. Furthermore, these results also imply that TNFα and PAI-1 may be considered as 
targets in the therapies but may be also in the prevention of NAFLD. However, this will have 
to be addressed in future studies.  
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Figure 15 Possible molecular mechanism involved in the development of fructose-induced fatty liver. 
Chronic intake of fructose may lead to elevated bacterial endotoxin levels in the portal blood and an activation of 
TLR-4 signaling cascades, subsequently leading to an increased formation of reactive oxygen species (ROS) and 
an nuclear factor-κB (NFκB)-dependent induction of tumor necrosis factor (TNFα). TNFα through its receptor 1 
can then cause insulin resistance (IR) in hepatocytes and an induction of plasminogen activator inhibitor (PAI-1) 
which in turn may through cMet-hepatocyte growth factor (HGF)-dependent pathways modulate hepatic lipid 
export, lipidation of cluster of differentiation 1d (CD1d) and NKT cell activation but also apoptosis. (Adapted 
from Kanuri G 2011) 
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5 Summary 
 
Non-alcoholic fatty liver disease (NAFLD), a liver disease frequently associated with obesity, 
type 2 diabetes and dyslipidemia has become a worldwide health problem during the last 
decades. Results of recent studies suggest that a diet rich in fructose may also be a risk factor 
for the development of NAFLD. Results of our own group but also other group suggest that 
TNFα and PAI-1 may be involved in the development of NAFLD in rodents but also humans. 
Therefore, the aim of the present study was to investigate the role TNFα and PAI-1 in the 
onset of fructose-induced NAFLD in a mouse model as well as in human NAFLD patients. 
The specific aims were 
 
1) Are TNFR1-/- mice protected from fructose-induced NAFLD? If yes, what are the 
molecular mechanisms involved? 
TNFR1 -/- and wild-type mice were either fed 30% fructose solution or tap water. Chronic 
fructose feeding caused a significant ~5-fold increase in triglyceride accumulation and 
neutrophil infiltration in livers of wild-type mice and an ~8-fold increase in plasma alanine 
aminotransferase (ALT) levels in comparison to control mice. Similar effects of fructose 
feeding were not found in TNFR 1-/- mice. Indeed, the protective effect of the tumor necrosis 
factor receptor 1 (TNFR1) deletion against the onset of fructose-induced steatosis was 
associated with decreased sterol regulatory element-binding protein 1 (SREBP-1), fatty acid 
synthase (FAS) and plasminogen activator inhibitor 1 (PAI-1) expression in the liver. 
Furthermore, the protective effect was also associated with protection against alterations 
markers of insulin signaling cascade (e.g. adenosine monophosphate-activated protein kinase 
(AMPK), protein kinase B (Akt) levels). However, markers of hepatic lipid peroxidation, 
inducible nitric oxide synthase (iNOS) protein and adenosine triphosphate (ATP) levels were 
similar between wild-type and TNFR1 -/- mice fed fructose. Taken together, these data 
suggest that TNFα plays a casual role in the onset of fructose-induced liver damage as well as 
insulin resistance in mice through signaling cascades downstream of TNFR1. 
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2) Are PAI-1-/- mice protected from fructose-induced NAFLD? And if so, what are the 
molecular mechanisms involved? 
To address if PAI-1 is also a critical factor in the onset of fructose-induced NAFLD, PAI-1-/- 
and wild-type mice were either fed a fructose solution or tap water. Chronic fructose feeding 
in wild-type mice caused a marked increase in hepatic triglycerides, PAI-1 expression and 
plasma ALT levels in comparison to water controls. A similar effect of fructose feeding was 
not found in PAI-1-/- mice. PAI-1-/- mice fed fructose were protected from hepatic steatosis 
despite similar portal endotoxin levels, alterations of markers of insulin resistance and hepatic 
TNFα protein levels between fructose fed groups. The protective effect of the loss of PAI-1 
against the onset of fructose-induced steatosis was associated with a significant increase in 
phospho-cMet, phospho Akt, expression of apolipoprotein B (ApoB) and activity of 
microsomal triglyceride transfer protein (MTTP) in livers of PAI-1-/- mice in comparison to 
fructose fed wild-type mice. Moreover, in PAI-1-/- mice expression of CD1d and markers of 
CD1d-reactive iNKT cells were markedly higher than in wild-type mice; however, expression 
of markers of activation of CD1d-reactive iNKT cells (e.g. interleukin 15 (IL-15) and 
interferon γ (INFγ)) were only found to be increased in livers of fructose fed PAI-1-/- mice. 
Taken together, these data suggest that PAI-1 plays a causal role in mediating the early phase 
of fructose-induced liver damage in mice through signalling cascades down-stream of Kupffer 
cells and TNFα.  
 
3) Are molecular mechanisms identified in mouse studies also relevant to human situation? 
 
To determine if the alterations found in livers of animals with NAFLD are also relevant in 
humans with NAFLD, markers of lipid peroxidation, insulin signaling and number of iNKT 
cells were determined in 6 controls and 11 NAFLD patients.4-hydroxynonenal (4-HNE) 
protein adducts levels were significantly higher in livers of NAFLD patients whereas 
expression of insulin receptor substrate (IRS-1) was reduced by ~80 % in comparison to 
controls. PAI-1 protein levels primarily found in hepatocytes was significantly higher in 
NAFLD patients; however, hepatic CD1d and MTTP mRNA expression did not differ 
between groups.  
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Hepatic c-Met and BCL-2l mRNA expressions were significantly lower in NAFLD patients in 
comparison to controls and number of CD3ζ positive cells was higher. In contrast, expression 
of iNKT cell markers (e.g. IL-4 and IL-15) was significantly lower in livers of patients with 
NAFLD when compared with controls.Taken together, the present study suggests that the 
molecular mechanism involved in the progression of NAFLD is similar in both rodents and 
humans. Furthermore, TNFα and PAI-1 may be considered as therapeutic targets for NAFLD. 
 
Zusammenfassung 
 
Die nicht-alkoholbedingte Fettlebererkrankung (NAFLD) ist eine Lebererkrankung, die 
häufig mit Übergewicht, Typ-2 Diabetes und Dyslipidämie assoziiert ist und somit in den 
letzten Jahrzehnten zu einem weltweiten Gesundheitsproblem wurde. Ergebnisse neuer 
Studien legen nahe, dass eine fruktose reiche Ernährung ein Risikofaktor für die Entwicklung 
von NAFLD ist. Nicht nur Ergebnisse der eigenen Arbeitsgruppe, sondern auch 
anderer Arbeitsgruppen legen nahe, dass TNFα und PAI-1 in der Entwicklung von NAFLD in 
Tiermodell aber auch Menschen beteiligt sein können. Vor diese HIntergrund war es das Ziel 
der vorliegenden Arbeit, die Rolle von TNFα und PAI-1 in der Entstehung einer fruktose-
induzierten NAFLD sowohl im Mausmodell als auch bei Patienten mit NAFLD zu 
untersuchen.  
Die spezifischen Ziele waren: 
 
1) Sind TNFR1-/- Mäuse vor der fruktose-induzierten NAFLD geschützt? Wenn ja, was sind 
die beteiligten molekularen Mechanismen? 
Tumornekrosefaktor-Rezeptor 1 (TNFR1)-/- und Wildtyp-Mäuse wurden entweder mit einer 
30%igen Fruktose-Lösung oder Wasser gefüttert. Die chronische Fütterung mit Fruktose 
führte zu einem signifikanten, ~5-fachen Anstieg der Triglyceridkonzentration und 
Neutrophileninfiltration in der Leber von Wildtypmäusen, sowie einem ~8-fachen Anstieg der 
Konzentration der Alanin-Aminotransferase (ALT) im Plasma im Vergleich zu den Kontroll 
mäusen. Ähnliche Effekte konnten in TNFR1-/- Mäusen nach der Fütterung mit Fruktose 
nicht nachgewiesen werden. Die protektive Wirkung des Verlustes TNFR1 gegenüber der 
fruktose-induzierten Steatose mit einer Verminderung der Expression des sterol regulatory 
element-binding protein 1 (SREBP-1), der Fettsäure-Synthase (FAS) und von PAI-1 in der 
Leber assoziiert. Darüber hinaus waren TNFR1-/- Mäuse auch vor veränderungen von  
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Markern der Insulin-Signalkaskade, wie der Adenosin-monophosphat-aktivierten 
Proteinkinase (AMPK) und der Proteinkinase B (Akt) geschützt. Jedoch fanden sich nur 
geringe Unterschiede in der hepatischen Lipidperoxidation, der Konzentration der 
induzierbaren Stickstoffmonoxid-Synthase (iNOS) und des Adenosintriphosphats (ATP)  
zwischen Wildtyp- und TNFR1-/- Mäusen nach Fruktosefütterung. Insgesamt, weisen die 
Ergebnisse darauf hin, dass TNFα eine wasentliche Rolle in der Entstehung  von fructose-
induzierte Leberschäden sowie der Insulin-Resistenz bei Mäusen  über dem TNFR1  
nachgeschalteten  Signalkaskaden  spielt. 
 
2) Sind PAI-1-/- Mäuse vor der fruktose-induzierten NAFLD geschützt? Wenn ja, was sind die 
beteiligten molekularen Mechanismen? 
 
Um zu untersuchen ob PAI-1 ebenfalls ein kritischer Faktor bei der Entstehung von fruktose-
induzierter NAFLD ist, wurden PAI-1-/- sowie Wildtyp-Mäuse entweder mit einer 
Fruktoselösung oder Wasser gefüttert. Die chronische Fütterung mit Fruktose führte in 
Wildtyp-Mäusen zu einem deutlichen Anstieg der Triglycerid-Konzentration in der Leber, der 
Expression von PAI-1 sowie der Plasma ALT-Spiegel im Vergleich zu den Wasserkontrollen. 
Eine ähnliche Wirkung der Fruktosefütterung auf PAI-1-/- Mäuse wurde nicht gefunden. So 
waren PAI-1-/- Mäuse vor der Lebersteatose trotz ähnlich hoher portaler Endotoxinspiegel, 
Insulinresistenz und hepatischer TNFα Konzentrationen geschützt. Die schützende Wirkung 
des PAI-1-Verlustes gegenüber der Entstehung von fruktose-induzierter Steatose war mit 
einer signifikanten Zunahme der Konzentration an phospho-c-Met, phospho Akt, der 
Expression von Apolipoprotein B (ApoB) sowie der Aktivität des mikrosomalen 
Triglyceridtransferporteins (MTTP) in den Lebern von PAI-1-/- Mäusen im Vergleich zu 
fruktose-gefütterten Wildtyp-Mäusen assoziert. Darüber hinaus war die Expression von CD1d 
und Markern von CD1d-reaktiven NKT Zellen in PAI-1-/- Mäusen deutlich höher als in den 
Wildtyp-Mäusen. Allerdings war die Expression der Aktivierungsmarker von CD1d-reaktiven 
NKT Zellen (z. B. Interleukin (IL) 15 und Interferon (IFN) γ) nur in den Lebern von fruktose-
gefütterten PAI-1-/- Mäusen erhöht. Insgesamt deuten  die Daten darauf hin, dass PAI-1 eine 
kausale Rolle in der Vermittlung der frühen Phase der fructose-induzierten Leberschädigung 
bei Mäusen über Signalkaskaden „down-stream“ der Kupffer-Zellen und von TNFα spielt. 
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3) Sind die in Mausstudien identifizierten, molekularen Mechanismen auf den Menschen 
übertragbar? 
Um festzustellen, ob die Veränderungen in der Leber von Tieren mit NAFLD auch für die 
Entstehung der NAFLD bei Menschen relevant sind, wurden Marker der Lipidperoxidation, 
Insulin-Signalkaskade und die Anzahl der iNKT-Zellen in 6 Kontrollen und 11 Patienten mit 
NAFLD bestimmt. Das Niveau an 4-HNE Proteinaddukten war in den Lebern der NAFLD-
Patienten signifikant erhöht, wohingegen die Expression von Insulin-Rezeptor-Substrat  (IRS-
1) im Vergleich zu den Kontrollen um ~80 % reduziert war. Die Konzentration an PAI-1 
Protein war in Patienten mit NAFLD signifikant höher wohingegen die mRNA-Expression 
von hepatischem CD1d und MTTP sich nicht zwischen den verschiedenen Gruppen 
unterschied. Die Hepatische c-Met sowie die BCL-21 mRNA Expression war bei NAFLD-
Patienten signifikant niedriger im Vergleich zu den Kontrollen, wohingegen die Anzahl der 
CD3ζ-positiven Zellen erhöht war. Im Gegensatz dazu war die Expression der iNKT-
Zellmarker IL-4 und IL-15 bei Patienten mit NAFLD signifikant niedriger als in den Lebern 
der Kontrollen. Insgesamt deuten die Ergebinesse der vorliegende Studie darauf hin, dass die 
bei der Progression der NAFLD beteiligten molekularen Mechanismen sowohl bei Nagern als 
auch bei Menschen ähnlich sind. Ferner können TNFα und PAI-1 in der Therapie der NAFLD 
von Bedeutung sein 
 
 
 
 
 
References 
 
84 
6 References 
 
 (1)  Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011 
May;48(3):97-113. 
 (2)  Adams LA, Lymp JF, St SJ, Sanderson SO, Lindor KD, Feldstein A, et al. The natural 
history of nonalcoholic fatty liver disease: a population-based cohort study. 
Gastroenterology 2005 Jul;129(1):113-121. 
 (3)  Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and 
the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J 
Clin Nutr 2004 May;79(5):774-779. 
 (4)  Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. 
Prevalence of hepatic steatosis in an urban population in the United States: impact of 
ethnicity. Hepatology 2004 Dec;40(6):1387-1395. 
 (5)  Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence 
of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver 
study. Hepatology 2005 Jul;42(1):44-52. 
 (6)  Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver 
abnormalities in severely obese subjects: effect of drastic weight loss after 
gastroplasty. Int J Obes Relat Metab Disord 1998 Mar;22(3):222-226. 
 (7)  Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, et al. Prevalence of and risk factors for 
fatty liver in a general population of Shanghai, China. J Hepatol 2005 Sep;43(3):508-
514. 
 (8)  Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of 
nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 
2001 Jul;121(1):91-100. 
 (9)  Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk 
factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol 
Hepatol 2006 Jan;21(1 Pt 1):138-143. 
 (10)  Karnikowski M, Cordova C, Oliveira RJ, Karnikowski MG, Nobrega OT. Non-
alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and 
older adults. Sao Paulo Med J 2007 Nov 1;125(6):333-337. 
 (11)  Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese 
population in a developing country has a high prevalence of nonalcoholic fatty liver 
and significant liver disease. Hepatology 2010 May;51(5):1593-1602. 
 (12)  Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in 
the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol 
Hepatol 2010 May;7(5):251-264. 
References 
 
85 
 
 (13)  Brun P, Castagliuolo I, Di L, V, Buda A, Pinzani M, Palu G, et al. Increased intestinal 
permeability in obese mice: new evidence in the pathogenesis of nonalcoholic 
steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007 Feb;292(2):G518-G525. 
 (14)  Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath 
ethanol concentration: potential implications for the pathogenesis of nonalcoholic 
steatohepatitis. Am J Gastroenterol 2001 Apr;96(4):1200-1204. 
 (15)  Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese 
mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000 
Nov;119(5):1340-1347. 
 (16)  Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic 
cirrhosis and in subjects with no evidence of chronic liver disease following acute 
alcohol excess. J Hepatol 1987 Feb;4(1):8-14. 
 (17)  Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. 
The role of small intestinal bacterial overgrowth, intestinal permeability, 
endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic 
steatohepatitis. Gut 2001 Feb;48(2):206-211. 
 (18)  Miele L, Valenza V, La TG, Montalto M, Cammarota G, Ricci R, et al. Increased 
intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. 
Hepatology 2009 Jun;49(6):1877-1887. 
 (19)  Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A, et al. 
Nonalcoholic fatty liver disease in humans is associated with increased plasma 
endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose 
intake. J Nutr 2008 Aug;138(8):1452-1455. 
 (20)  Volynets V, Kuper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, et al. 
Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients 
with Nonalcoholic Fatty Liver Disease (NAFLD). Dig Dis Sci 2012 Mar 17. 
 (21)  Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, et al. Antibiotics 
protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. 
J Hepatol 2008 Jun;48(6):983-992. 
 (22)  Wheeler MD. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol 
Res Health 2003;27(4):300-306. 
 (23)  Akira S, Hoshino K, Kaisho T. The role of Toll-like receptors and MyD88 in innate 
immune responses. J Endotoxin Res 2000;6(5):383-387. 
 (24)  Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell 
activation. Am J Physiol Gastrointest Liver Physiol 2002 Aug;283(2):G256-G265. 
References 
 
86 
 
 (25)  Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: 
effects of ethanol per se or enhanced intestinal translocation of bacterial toxins 
induced by ethanol? Alcohol Clin Exp Res 2005 Nov;29(11 Suppl):166S-171S. 
 (26)  Iida S, Ohshima H, Oguchi S, Hata T, Suzuki H, Kawasaki H, et al. Identification of 
inducible calmodulin-dependent nitric oxide synthase in the liver of rats. J Biol Chem 
1992 Dec 15;267(35):25385-25388. 
 (27)  Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour 
necrosis factor alpha signalling through activation of Kupffer cells plays an essential 
role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006 Mar;55(3):415-
424. 
 (28)  Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and 
insulin resistance by increasing hepatic NKT cells. J Hepatol 2008 Nov;49(5):821-
830. 
 (29)  Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, Estebanez A, et al. 
Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene 
expression in obese patients: evidence for the potential role of endotoxin in the 
pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007 Oct;17(10):1374-1380. 
 (30)  Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH 
predicts plasma inflammatory biomarkers independently of visceral fat in men. 
Obesity (Silver Spring) 2008 Jun;16(6):1394-1399. 
 (31)  Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, et al. Plasma PAI-
1 levels are more strongly related to liver steatosis than to adipose tissue 
accumulation. Arterioscler Thromb Vasc Biol 2003 Jul 1;23(7):1262-1268. 
 (32)  Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, et al. Metformin 
prevents alcohol-induced liver injury in the mouse: Critical role of plasminogen 
activator inhibitor-1. Gastroenterology 2006 Jun;130(7):2099-2112. 
 (33)  Kruithof EK. Plasminogen activator inhibitors--a review. Enzyme 1988;40(2-3):113-
121. 
 (34)  Arteel GE. New role of plasminogen activator inhibitor-1 in alcohol-induced liver 
injury. J Gastroenterol Hepatol 2008 Mar;23 Suppl 1:S54-S59. 
 (35)  Hanover LM, White JS. Manufacturing, composition, and applications of fructose. Am 
J Clin Nutr 1993 Nov;58(5 Suppl):724S-732S. 
 (36)  US Department of Agriculture. The food pyramid.  US Dept of Agriculture; 1992.  
 (37)  Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose 
consumption among US children and adults: the Third National Health and Nutrition 
Examination Survey. Medscape J Med 2008;10(7):160. 
References 
 
87 
 
 (38)  Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased 
from 1977 to 2004 in the United States. J Nutr 2009 Jun;139(6):1228S-1235S. 
 (39)  Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in 
beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004 
Apr;79(4):537-543. 
 (40)  Leclercq C, Arcella D, Piccinelli R, Sette S, Le DC, Turrini A. The Italian National 
Food Consumption Survey INRAN-SCAI 2005-06: main results in terms of food 
consumption. Public Health Nutr 2009 Dec;12(12):2504-2532. 
 (41)  Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. 
Physiol Rev 2010 Jan;90(1):23-46. 
 (42)  Jalal DI, Smits G, Johnson RJ, Chonchol M. Increased fructose associates with 
elevated blood pressure. J Am Soc Nephrol 2010 Sep;21(9):1543-1549. 
 (43)  Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. Caloric 
sweetener consumption and dyslipidemia among US adults. JAMA 2010 Apr 
21;303(15):1490-1497. 
 (44)  Montonen J, Jarvinen R, Knekt P, Heliovaara M, Reunanen A. Consumption of 
sweetened beverages and intakes of fructose and glucose predict type 2 diabetes 
occurrence. J Nutr 2007 Jun;137(6):1447-1454. 
 (45)  Dhingra R, Sullivan L, Jacques PF, Wang TJ, Fox CS, Meigs JB, et al. Soft drink 
consumption and risk of developing cardiometabolic risk factors and the metabolic 
syndrome in middle-aged adults in the community. Circulation 2007 Jul 
31;116(5):480-488. 
 (46)  Anderson JW, Story LJ, Zettwoch NC, Gustafson NJ, Jefferson BS. Metabolic effects 
of fructose supplementation in diabetic individuals. Diabetes Care 1989 
May;12(5):337-344. 
 (47)  Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, Lillo JL. 
Excessive fructose intake induces the features of metabolic syndrome in healthy adult 
men: role of uric acid in the hypertensive response. Int J Obes (Lond) 2010 
Mar;34(3):454-461. 
 (48)  Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. 
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral 
adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J 
Clin Invest 2009 May;119(5):1322-1334. 
 (49)  Le KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, et al. Fructose overconsumption 
causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a 
family history of type 2 diabetes. Am J Clin Nutr 2009 Jun;89(6):1760-1765. 
References 
 
88 
 
 (50)  Castello A, Guma A, Sevilla L, Furriols M, Testar X, Palacin M, et al. Regulation of 
GLUT5 gene expression in rat intestinal mucosa: regional distribution, circadian 
rhythm, perinatal development and effect of diabetes. Biochem J 1995 Jul 1;309 ( Pt 
1):271-277. 
 (51)  Cheeseman CI. GLUT2 is the transporter for fructose across the rat intestinal 
basolateral membrane. Gastroenterology 1993 Oct;105(4):1050-1056. 
 (52)  Colville CA, Seatter MJ, Jess TJ, Gould GW, Thomas HM. Kinetic analysis of the 
liver-type (GLUT2) and brain-type (GLUT3) glucose transporters in Xenopus oocytes: 
substrate specificities and effects of transport inhibitors. Biochem J 1993 Mar 15;290 ( 
Pt 3):701-706. 
 (53)  Rutledge AC, Adeli K. Fructose and the metabolic syndrome: pathophysiology and 
molecular mechanisms. Nutr Rev 2007 Jun;65(6 Pt 2):S13-S23. 
 (54)  Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. 
Increased fructose consumption is associated with fibrosis severity in patients with 
nonalcoholic fatty liver disease. Hepatology 2010 Jun;51(6):1961-1971. 
 (55)  Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. 
Long term nutritional intake and the risk for non-alcoholic fatty liver disease 
(NAFLD): a population based study. J Hepatol 2007 Nov;47(5):711-717. 
 (56)  Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose 
consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008 
Jun;48(6):993-999. 
 (57)  Armutcu F, Coskun O, Gurel A, Kanter M, Can M, Ucar F, et al. Thymosin alpha 1 
attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. 
Clin Biochem 2005 Jun;38(6):540-547. 
 (58)  Jurgens H, Haass W, Castaneda TR, Schurmann A, Koebnick C, Dombrowski F, et al. 
Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res 
2005 Jul;13(7):1146-1156. 
 (59)  Faeh D, Minehira K, Schwarz JM, Periasamy R, Park S, Tappy L. Effect of fructose 
overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin 
sensitivity in healthy men. Diabetes 2005 Jul;54(7):1907-1913. 
 (60)  Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like 
receptor 4 is involved in the development of fructose-induced hepatic steatosis in 
mice. Hepatology 2009 Oct;50(4):1094-1104. 
 (61)  Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I. Role of the inducible nitric 
oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox 
Signal 2011 Jun;14(11):2121-2135. 
References 
 
89 
 
 (62)  Spruss A, Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in 
the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 2009 
Sep;20(9):657-662. 
 (63)  Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. 
Biotechnology 1992;24:145-149. 
 (64)  Folch J, LEES M, SLOANE STANLEY GH. A simple method for the isolation and 
purification of total lipides from animal tissues. J Biol Chem 1957 May;226(1):497-
509. 
 (65)  Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and 
chemokines in the development of steatohepatitis. Semin Liver Dis 2007 
May;27(2):173-193. 
 (66)  Latta M, Kunstle G, Lucas R, Hentze H, Wendel A. ATP-depleting carbohydrates 
prevent tumor necrosis factor receptor 1-dependent apoptotic and necrotic liver injury 
in mice. J Pharmacol Exp Ther 2007 Jun;321(3):875-883. 
 (67)  Malaguarnera M, Di RM, Nicoletti F, Malaguarnera L. Molecular mechanisms 
involved in NAFLD progression. J Mol Med 2009 Apr 8;87:679-695. 
 (68)  Arteel GE. Oxidants and antioxidants in alcohol-induced liver disease. 
Gastroenterology 2003 Mar;124(3):778-790. 
 (69)  Kotani K, Peroni OD, Minokoshi Y, Boss O, Kahn BB. GLUT4 glucose transporter 
deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin 
Invest 2004 Dec;114(11):1666-1675. 
 (70)  Taher TE, Tjin EP, Beuling EA, Borst J, Spaargaren M, Pals ST. c-Cbl is involved in 
Met signaling in B cells and mediates hepatocyte growth factor-induced receptor 
ubiquitination. J Immunol 2002 Oct 1;169(7):3793-3800. 
 (71)  Suzuki H, Toyoda M, Horiguchi N, Kakizaki S, Ohyama T, Takizawa D, et al. 
Hepatocyte growth factor protects against Fas-mediated liver apoptosis in transgenic 
mice. Liver Int 2009 Nov;29(10):1562-1568. 
 (72)  Kaser A, Hava DL, Dougan SK, Chen Z, Zeissig S, Brenner MB, et al. Microsomal 
triglyceride transfer protein regulates endogenous and exogenous antigen presentation 
by group 1 CD1 molecules. Eur J Immunol 2008 Aug;38(8):2351-2359. 
 (73)  Dougan SK, Salas A, Rava P, Agyemang A, Kaser A, Morrison J, et al. Microsomal 
triglyceride transfer protein lipidation and control of CD1d on antigen-presenting 
cells. J Exp Med 2005 Aug 15;202(4):529-539. 
 (74)  Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor 
necrosis factor alpha (TNFalpha) in the onset of fructose-induced nonalcoholic fatty 
liver disease in mice. J Nutr Biochem 2011 Jun;22(6):527-534. 
References 
 
90 
 
 (75)  Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Fructose-induced 
steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride 
transfer protein and NKT cells. Lab Invest 2011 Jun;91(6):885-895. 
 (76)  Forshee RA, Storey ML, Allison DB, Glinsmann WH, Hein GL, Lineback DR, et al. 
A critical examination of the evidence relating high fructose corn syrup and weight 
gain. Crit Rev Food Sci Nutr 2007;47(6):561-582. 
 (77)  Assy N, Nasser G, Kamayse I, Nseir W, Beniashvili Z, Djibre A, et al. Soft drink 
consumption linked with fatty liver in the absence of traditional risk factors. Can J 
Gastroenterol 2008 Oct;22(10):811-816. 
 (78)  Lewis GF, Murdoch S, Uffelman K, Naples M, Szeto L, Albers A, et al. Hepatic lipase 
mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, 
fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer 
rosiglitazone. Diabetes 2004 Nov;53(11):2893-2900. 
 (79)  Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T. Lipopolysaccharide 
triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic 
steatohepatitis model. J Hepatol 2009 Jul;51(1):168-175. 
 (80)  Crespo J, Fernandez-Gil P, Hernandez-Guerra M, Cayon A, Mayorga M, Dominguez-
Diez A, et al. Are there predictive factors of severe liver fibrosis in morbidly obese 
patients with non-alcoholic steatohepatitis? Obes Surg 2001 Jun;11(3):254-257. 
 (81)  Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies 
to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. 
Hepatology 2003 Feb;37(2):343-350. 
 (82)  Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity 
promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF 
expression. Cell 2010 Jan 22;140(2):197-208. 
 (83)  Han D, Ybanez MD, Ahmadi S, Yeh K, Kaplowitz N. Redox regulation of tumor 
necrosis factor signaling. Antioxid Redox Signal 2009 Sep;11(9):2245-2263. 
 (84)  Latta M, Kunstle G, Leist M, Wendel A. Metabolic depletion of ATP by fructose 
inversely controls. J Exp Med 2000 Jun 5;191(11):1975-1985. 
 (85)  Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic 
insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat 
Med 2005 Feb;11(2):183-190. 
 (86)  Yan J, Gao Z, Yu G, He Q, Weng J, Ye J. Nuclear corepressor is required for 
inhibition of phosphoenolpyruvate carboxykinase expression by tumor necrosis factor-
alpha. Mol Endocrinol 2007 Jul;21(7):1630-1641. 
References 
 
91 
 
 (87)  Lim JH, Lee HJ, Ho JM, Song J. Coupling mitochondrial dysfunction to endoplasmic 
reticulum stress response: a molecular mechanism leading to hepatic insulin 
resistance. Cell Signal 2009 Jan;21(1):169-177. 
 (88)  Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-
activated protein kinase in mechanism of metformin action. J Clin Invest 2001 
Oct;108(8):1167-1174. 
 (89)  Woods A, zzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, et al. 
Characterization of the role of AMP-activated protein kinase in the regulation of 
glucose-activated gene expression using constitutively active and dominant negative 
forms of the kinase. Mol Cell Biol 2000 Sep;20(18):6704-6711. 
 (90)  Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological 
activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a 
stoichiometric reaction. J Biol Chem 1995 Jan 13;270(2):603-611. 
 (91)  Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei K, et al. 
Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to 
prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic 
hamsters. Circulation 2000 Jul 11;102(2):246-252. 
 (92)  Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. 
Minerva Cardioangiol 2006 Apr;54(2):229-239. 
 (93)  Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, et al. Involvement of PI3K/Akt signaling 
pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. 
Invest Ophthalmol Vis Sci 2008 Feb;49(2):497-504. 
 (94)  Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, et al. HGF/c-Met 
pathway has a prominent role in mediating antiapoptotic signals through AKT in 
epithelial ovarian carcinoma. Lab Invest 2011 Jan;91(1):124-137. 
 (95)  Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator 
inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator 
inhibitor-1-deficient endothelial cells. J Biol Chem 2006 Aug 11;281(32):22527-
22536. 
 (96)  Garcia-Ocana A, Vasavada RC, Cebrian A, Reddy V, Takane KK, Lopez-Talavera JC, 
et al. Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly 
improves islet function and islet transplant outcomes in mice. Diabetes 2001 
Dec;50(12):2752-2762. 
 (97)  Brozovic S, Nagaishi T, Yoshida M, Betz S, Salas A, Chen D, et al. CD1d function is 
regulated by microsomal triglyceride transfer protein. Nat Med 2004 May;10(5):535-
539. 
References 
 
92 
 
 (98)  Dougan SK, Rava P, Hussain MM, Blumberg RS. MTP regulated by an alternate 
promoter is essential for NKT cell development. J Exp Med 2007 Mar 19;204(3):533-
545. 
 (99)  Kotas ME, Lee HY, Gillum MP, Annicelli C, Guigni BA, Shulman GI, et al. Impact of 
CD1d deficiency on metabolism. PLoS One 2011;6(9):e25478. 
 (100)  Elinav E, Pappo O, Sklair-Levy M, Margalit M, Shibolet O, Gomori M, et al. 
Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic 
steatohepatitis and glucose intolerance in ob/ob mice and is associated with 
intrahepatic CD8 trapping. J Pathol 2006 May;209(1):121-128. 
 (101)  Li Z, Oben JA, Yang S, Lin H, Stafford EA, Soloski MJ, et al. Norepinephrine 
regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic 
steatohepatitis. Hepatology 2004 Aug;40(2):434-441. 
 (102)  Yang L, Jhaveri R, Huang J, Qi Y, Diehl AM. Endoplasmic reticulum stress, 
hepatocyte CD1d and NKT cell abnormalities in murine fatty livers. Lab Invest 2007 
Sep;87(9):927-937. 
 (103)  Kremer M, Thomas E, Milton RJ, Perry AW, van RN, Wheeler MD, et al. Kupffer cell 
and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. 
Hepatology 2010 Jan;51(1):130-141. 
 (104)  Suzuki A, McCall S, Choi SS, Sicklick JK, Huang J, Qi Y, et al. Interleukin-15 
increases hepatic regenerative activity. J Hepatol 2006 Sep;45(3):410-418. 
 (105)  Zeng J, Howard JC. Spontaneous focal activation of invariant natural killer T (iNKT) 
cells in mouse liver and kidney. BMC Biol 2010;8:142. 
 (106)  Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, et al. Constitutive 
cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector 
function. J Exp Med 2003 Oct 6;198(7):1069-1076. 
 (107)  Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of 
lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J 
Hepatol 2002 Jul;37(1):56-62. 
 (108)  Das KS, Balakrishnan V, Mukherjee S, Vasudevan DM. Evaluation of blood oxidative 
stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver 
disease. Scand J Clin Lab Invest 2008;68(4):323-334. 
 (109)  Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin 
Endocrinol Diabetes 1999;107(2):119-125. 
 (110)  Li L, He Q, Huang X, Man Y, Zhou Y, Wang S, et al. NOX3-derived reactive oxygen 
species promote TNF-alpha-induced reductions in hepatocyte glycogen levels via a 
JNK pathway. FEBS Lett 2010 Mar 5;584(5):995-1000. 
References 
 
93 
 
 (111)  Garcia-Monzon C, Lo IO, Mayoral R, Gonzalez-Rodriguez A, Miquilena-Colina ME, 
Lozano-Rodriguez T, et al. Hepatic insulin resistance is associated with increased 
apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J 
Hepatol 2011 Jan;54(1):142-152. 
 (112)  Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin 
resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV 
RNA level, and liver fibrosis. Gastroenterology 2008 Feb;134(2):416-423. 
 (113)  Romero-Gomez M, Del M, V, Andrade RJ, Salmeron J, Diago M, Fernandez-
Rodriguez CM, et al. Insulin resistance impairs sustained response rate to 
peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 
Mar;128(3):636-641. 
 (114)  Kaibori M, Kwon AH, Oda M, Kamiyama Y, Kitamura N, Okumura T. Hepatocyte 
growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat 
hepatocytes. Hepatology 1998 May;27(5):1354-1361. 
 (115)  Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) 
regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid 
Res 1995 May;36(5):1073-1081. 
 (116)  Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating 
CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver 
disease. Eur J Gastroenterol Hepatol 2009 Jun;21(6):673-680. 
 (117)  Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, et al. Accumulation of 
natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 2010 
Jun;51(6):1998-2007. 
 
 
 
Acknowledgements 
 
 
I wish my extreme thanks to Prof. Dr. med. Stephan C. Bischoff, Head, Institute of Nutritional 
Medicine and Prevention (180) for allowing and guiding me to do this thesis in his reputed 
laboratory. 
 
I would also extend my sincere thanks to Prof. Dr. Lutz Graeve Institute of Biological 
chemistry and Nutrition (140c) for his guidance. 
 
I express my deep sense of gratitude to PD Dr. Ina Bergheim, Institute of Nutritional 
Medicine and Prevention (180) for her excellent guidance and moral support during my 
thesis. 
 
I would like to convey my special thanks to all my colleagues for their help and 
encouragement. 
 
I convey my special thanks to my family for their continuous support in pursuing my work 
successfully. 
 
My special thanks to Elsevier and Nature publishing group for publishing the work and 
allowing me reuse in the thesis. 
 
I would also like to extend my deep sense of gratitude to all my friends, who made my social 
life better in Hohenheim. 
 
         Giridhar Kanuri 
 
 
 
 
Declaration 
 
 
I here by declare that this work has been originally carried out by me under the supervision of 
Prof. Dr. med. Stephan C. Bischoff, Head, Department of Nutritional Medicine and 
Prevention (180) and co-guided by Prof. Dr. Lutz Graeve. I have written this thesis by my 
own. Furthermore, I confirm that no other sources have been used than those specified in the 
thesis itself.  
 
I further assure that this work has not been submitted either in whole or part for any other 
degree at any other university. 
 
 
 
 
 
 
          Giridhar Kanuri 
 
